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William Bruce Cameron 
 
1 Cor 13:1-2 
 
 
  
   
  
ABSTRACT 
Platelet function is central to atherothombotic diseases and antiplatelet agents prevent non-
cardioembolic ischemic stroke (IS). Individual differences in platelet reactivity may limit the 
response to antiplatelet treatment, leading to so-called high on-treatment platelet reactivity 
(HPR). HPR is associated with increased risk of cardiovascular events. Platelet activation 
leads to the release of platelet microvesicles (PMV), and circulating PMV are considered a 
measure of in vivo platelet function. Activated platelets and PMV enhance thrombin 
generation and thrombin in turn is a strong platelet agonist.  
The overall aim of this thesis was to study the importance of platelet function, circulating 
PMV, thrombin generation and associations with clinical characteristics and prognosis in 
patients with IS or transient ischemic attack (TIA). 
The prevalence of HPR to clopidogrel was assessed by whole blood aggregation in a cross-
sectional study of 72 patients treated with clopidogrel one month after IS or TIA. 
Associations between HPR and clinical variables were determined, focusing on glucose 
metabolism, IS subtype and arterial vessel changes (study 1 and 2). Circulating PMV, 
expressing activation markers P-selectin or tissue factor (TF), and thrombin generation 
variables were measured in the acute and convalescent phase of IS/TIA in a cohort study of 
211 patients (study 3 and 4). Associations with prognosis were evaluated after a 5 to 7 year 
follow-up. The primary outcome was a composite of recurrent IS, myocardial infarction and 
ischemic cardiovascular death; recurrent IS was a secondary outcome.  
HPR to clopidogrel was found in 16/72 IS/TIA patients (22%) and was associated impaired 
glucose tolerance/diabetes, insulin resistance, hypertension and radiological white matter 
changes (WMC), indicating cerebral small vessel disease (CSVD). There were no 
associations between HPR and carotid atherosclerosis, other manifestations of large vessel 
atherosclerosis or IS stroke subtype.  
PMV populations expressing P-selectin or TF were substantially elevated in the acute phase 
of IS/TIA, and remained elevated in the convalescent phase. Only PMV expressing TF and 
lacking phosphatidylserine (PS) were associated with poor outcome, with a hazard ratio (HR) 
of 1.86 [1.04-3.31] p=0.036 after adjustment for cardiovascular risk factors. Unexpectedly, 
high levels of several PMV populations appeared inversely associated with poor outcome. 
Despite being elevated in patients, endogenous thrombin generation potential (ETP) and peak 
thrombin measured in the acute phase were associated with reduced risks of primary outcome 
and recurrent IS after adjustment for cardiovascular risk factors, HR 0.40-0.53, p < 0.05 for 
all. MV-induced thrombin generation potential and MV peak thrombin were associated with 
increased risk of recurrent IS in univariate analysis. F1+2 was lower in patients than healthy 
controls, but not associated with outcome. There were no correlations between thrombin 
generation variables and PMV populations. 
In summary, HPR to clopidogrel in patients with IS or TIA was common and the risk of HPR 
increased in the pre-diabetic phase. HPR was associated with CSVD but not with large artery 
atherosclerosis. Circulating levels of PMV populations after an episode of IS/TIA had 
different associations with outcome; PMV expressing TF but lacking PS merit further 
investigation as they were associated poor prognosis. High levels of ETP and peak thrombin 
in the acute phase were associated with reduced risk of recurrence, while MV-induced 
thrombin generation was associated with increased risk of recurrent IS.  
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1 INTRODUCTION 
1.1 GENERAL BACKGROUND 
Stroke is the second most common cardiovascular disease after coronary artery disease 
(CAD) and a major cause of death and disability in Sweden and globally. The majority of 
strokes are ischemic (85%), caused by a thrombus or embolus occluding a cerebral artery. 
Ischemic stroke (IS) is a heterogeneous condition with different underlying pathologies. The 
three major IS subtypes are large artery atherosclerosis, small vessel disease and 
cardioembolism, which is often caused by atrial fibrillation (AF).  
In the absence of cardioembolism, antiplatelet treatment is given as secondary prophylaxis 
after IS or transient ischemic attack (TIA). Platelets have a direct role in arterial thrombus 
formation following rupture of an atherosclerotic plaque. Mounting evidence suggests that 
platelets also have a role in the atherosclerotic process (1-3). While intensified platelet 
inhibition has resulted in net clinical benefits for patients with acute coronary syndrome 
(ACS), this has not always been the case for patients with IS as several studies have shown a 
marginal improvement which has often been offset by an increased risk of major bleeding (4, 
5).  
The view of platelet function in hemostasis and thrombosis has evolved substantially over the 
last 10-20 years. It has been shown that there are individual differences in the response to 
antiplatelet treatment, in particular to clopidogrel but also to aspirin, so-called high on-
treatment platelet reactivity (HPR) (6, 7). Platelets have been found to have an important role 
in inflammation, interacting with the endothelium and leukocytes (8). Upon activation 
platelets release microvesicles (MV) into the circulation which stimulate coagulation (9); 
further activated platelets bind MV in the thrombus which promote fibrin formation (10). 
Most of the clinical studies on platelet function in cardiovascular disease (CVD) have been 
performed in patients with CAD. However, patients with IS differ from those with CAD in 
risk factor profile, underlying vessel pathology, acute treatment and bleeding risk. Therefore 
the aim of this thesis was to investigate platelet function in patients with IS or TIA, focusing 
on HPR and MV.  
1.2 CLINICAL ASPECTS OF STROKE AND STROKE SUBTYPES 
1.2.1 Stroke epidemiology and risk factors 
The updated stroke definition recognizes stroke as one manifestation of cerebrovascular 
diseases (11). Stroke is defined as acute, focal neurological symptoms persisting for more 
than 24 hours, or typical symptoms of shorter duration with radiological evidence of an acute 
lesion in an appropriate neuroanatomical location (11). If the symptom duration less than 24 
hours and no corresponding lesion is found, the patient is diagnosed with TIA. Patients with 
TIA have a substantial risk of developing IS in the following weeks-months.  
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The stroke incidence in Sweden is presently about 25 000 per year (12). In addition there are 
about 10 000 cases of TIA per year. About one quarter of strokes are recurrent events. The 
incidence of stroke in Sweden has decreased by approximately 2000 cases per year in the last 
decade (12). This is likely due to improved risk factor control in the population with 
improved treatment of hypertension and hyperlipidemia, increased anticoagulant treatment of 
AF and reduced rates of smoking. The risk of recurrent IS remains relatively high despite 
secondary prevention: 3-7% in the first three months after IS/TIA and thereafter 2-3%/year in 
modern intervention studies (13, 14).  
The main risk factors for stroke are the established cardiovascular risk factors, but their 
relative importance differs from those of other CVD. Hypertension is by far the most 
important risk factor, giving an odds ratio (OR) of about 3 and globally representing about 
half of the population attributable risk (15). Age is a strong, non-modifiable risk factor, and 
the average age is higher for stroke patients than for patients with acute myocardial infarction 
(AMI) (16). Male sex is not a clear risk factor for stroke overall (16). Smoking is a risk factor 
for stroke with an OR 1.7 and dose-dependent increase of risk for current smokers (15, 16). 
Diabetes increases the relative risk of stroke (16), but epidemiologic studies show a limited 
independent contribution to the population attributable risk (15). Other aspects of the 
metabolic syndrome such as waist-to-hip ratio or BMI may be more important for stroke (15, 
17). Hyperlipidemia is a risk factor for stroke, but statin treatment reduces the risk of 
recurrence less after IS than after AMI (18, 19). Overall smoking, diabetes and 
hyperlipidemia are all weaker risk factors for stroke than for AMI (15, 20). High alcohol 
consumption increases the risk for stroke with an OR of about 2 (15), while for AMI 
moderate alcohol consumption overall is protective (20). Stress, low level of exercise and a 
diet low in fruit and vegetables are important modifiable risk factors (15). AF and carotid 
stenosis are etiological risk factors, as discussed below.  
Hemorrhagic stroke or intracerebral hemorrhages (ICH) comprise about 15% of strokes. The 
main risk factors for ICH are hypertension, alcohol and stress (15). The most common forms 
of ICH are hypertensive ICH and subarachnoid hemorrhage, where the latter is often caused 
by a ruptured cerebral aneurysm. Rare causes include cerebral amyloid angiopathy (CAA), 
vessel malformations and tumors.  
IS has many different causes. According to a recent large meta-analysis, cardioembolism 
causes 22% of IS, large artery atherosclerosis 23% and small vessel disease 22% (21). In 
26% of cases the cause was undetermined, which includes the cases where no cause can be 
determined, so-called cryptogenic stroke. Other determined causes contributed 3% of IS, 
including conditions such as dissection of cerebral vessels, venous sinous thrombosis, 
migraine, vasculitis and prothrombotic/procoagulant conditions. The distribution of IS 
subtypes varies depending on ethnic background and socioeconomic conditions (21).  
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1.2.2 Ischemic stroke subtypes 
1.2.2.1 Cardioembolism 
Cardioembolism involves thrombus formation in the heart, often due to disturbed flow 
conditions. The thrombus, or part of it, may release, follow the blood stream and cause 
occlusion of cerebral arteries. AF is by far the most common cause, with thrombi often 
forming in the left atrial appendage. Other underlying conditions include left ventricular 
mural thrombus due to AMI or pronounced heart failure, valvular heart disease (in particular 
mitral stenosis), thrombus formation on mechanic valve prostheses (often due to inadequate 
anticoagulation), endocarditis, cardiac tumors and patent foramen ovale with paradoxical 
embolism from the venous system.  
AF is common with an estimated prevalence of 3% in adults and higher in the elderly (22). In 
AF, the electrical conduction system of the heart is disturbed by micro-reentry circuits in the 
atria, causing fast and irregular atrial contractions. The ventricular heart rate is also irregular 
as only random electrical impulses pass the atrial-ventricular node. Factors that increase the 
risk for AF include structural heart disease, hypertension and possibly diabetes (22). The 
pathology of AF is characterized by structural remodeling with atrial distension, cardiac 
fibrosis and endocardial damage. These factors both increase the risk of AF and are 
aggravated by AF, creating a viscous circle (23). Overall, AF increases the risk for IS by a 
factor 2-5, where the individual risk depends on comorbidities/cardiovascular risk factors. 
These are often summed up in scores, and the CHA2DS2-VASc score (0-9 points) is presently 
the one recommended (22). The yearly risk of IS due to AF in Sweden varies between 0 and 
17% from the lowest to the highest CHA2DS2-VASc score (24). Other scores are investigated 
to improve the prediction of which AF patients are at risk of IS/thromboembolism (25). 
Factors that contribute to thrombus formation in AF are stasis of blood flow, activated 
coagulation and endocardial damage/activation (23). Certain plasma platelet activation 
markers have also been found elevated, which may however be secondary to underlying 
cardiovascular disease or comorbidities (23). Anticoagulant treatment is given to prevent IS 
caused by AF or other forms of cardioembolism. Further discussion cardioembolic IS will be 
limited in this thesis, which concerns primarily non-cardioembolic IS.  
1.2.2.2 Large artery atherosclerosis 
Atherosclerosis with stenosis of the carotid bifurcation or proximal internal carotid artery is 
estimated to cause 10% of IS. IS can also be caused by large artery atherosclerosis of the 
intracranial vessels, vertebral or basilar arteries or more proximal vessels including the aortic 
arch. IS due to large artery atherosclerosis has the strongest commonality to AMI. However, 
in contrast to AMI, where plaque rupture often leads artery occlusion in direct proximity to 
the plaque, large artery IS often involves artery-to-artery embolization.  
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The development of atherosclerotic plaque is a complex process stretching over many years, 
often decades. Only some key events in plaque development will be mentioned here (26). 
Plaque typically form at artery branch points or areas of turbulent blood flow. The initial 
lesion, the fatty streak, results from accumulation of lipoproteins in the intima layer of the 
artery wall, where they bind to proteoglycans. Once resident in the vessel wall, lipoproteins 
are prone to oxidization which generates pro-inflammatory breakdown products. These cause 
endothelial dysfunction and recruitment of leukocytes to the lesion. Amongst others 
monocytes transmigrate into the intima, and differentiate into macrophages which 
phagocytize oxidized low-density lipoprotein (ox-LDL) and transform into foam cells. Foam 
cells may undergo apoptosis, enhancing lipid accumulation. The inflammatory reaction leads 
to recruitment of vascular smooth muscle cells (VSCM) from the arterial wall media. In 
response to inflammatory cytokines, in particular platelet-derived growth factor and 
transforming growth factor β, VSCM proliferate and produce extracellular matrix, resulting 
in progression to a fibrofatty lesion. Activation of platelets and the coagulation system occur 
in association to the lesion, resulting in microthrombi, which contribute to plaque 
progression, hence the term atherothrombosis. As plaques become larger and more 
complicated they may develop a necrotic core, neovascularization and a thin fibrous cap, all 
of which contribute to plaque instability and risk of rupture. Plaque rupture exposes collagen 
and tissue factor (TF) which activate platelets and the coagulation system leading to thrombus 
formation.  
1.2.2.3 Cerebral small vessel disease 
Cerebral small vessel disease (CSVD) is the most common cause of so-called lacunar 
infarcts, which are often central infarcts with a size less than 20 mm in the acute phase. 
CSVD is a collective term for different pathological changes in penetrating arteries and 
arterioles less than 0.5 mm in diameter; cerebral venules and capillaries may also be affected 
(27, 28). The general characteristic of CSVD is a spread but segmental breakdown of the 
vessel wall architecture. CSVD may manifest as different cerebral lesions detectable with 
magnetic resonance imaging (MRI) (29):  
• Small subcortical infarcts 
• Lacunes of presumed vascular origin 
• White matter changes (WMC) 
• Expanded perivascular spaces 
• Cerebral microbleeds 
• Large ICH (deep or lobar) 
• Brain atrophy 
Sporadic CSVD is considered to have two major causes: hypertensive arteriolosclerosis and 
CAA (27). These manifest in different locations with hypertensive changes typically 
occurring in deep, central structures and CAA in subcortical, cortical and leptomeningeal 
arteries. The two conditions may co-exist.  
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Increasingly, CSVD is considered a syndrome affecting the whole brain (30). In the absence 
of stroke, CSVD may cause cognitive decline, gait disturbances, mood disorders and urinary 
incontinence. A meta-analysis of population-based studies of WMC, considered to be the 
earliest and most common CSVD lesion, showed that WMC increase the risks of stroke 
(hazard ratio, HR 3.3), dementia (HR 1.9) and death (HR 2.0) (31). While the short-term 
prognosis of lacunar infarcts is generally good, the medium to long term prognosis is worse, 
with an increased risk of all the above-mentioned complications. 
The etiology of CSVD has remained elusive, and there is limited knowledge as to which 
patients develop clinical symptoms from CSVD, which progress radiologically/clinically and 
why patients develop certain CSVD manifestations and not others. In population-based 
studies, cardiovascular risk factors are associated with WMC and lacunes, in particular 
hypertension and age. However, cardiovascular risk factors are not substantially more 
common in patients with clinical lacunar infarcts than in patients with IS of other subtypes 
(32, 33). Also, a recent study showed that cardiovascular risk factors explained a very limited 
part of the variance in WMC in both a population-based and a stroke cohort (34). The authors 
concluded that CSVD has primarily a ‘non-atheromatous’ etiology. Hereditary factors are 
important (35, 36) and genome-wide association studies have identified certain candidate 
genes for IS caused by CSVD (37).  
The pathology of lacunar infarcts was first characterized in ground-breaking work by Fisher 
1960’s (38). In the majority of cases, the artery supplying a lacune was occluded.  
Characteristic vessel changes included segmental lipohyalinosis with arterial wall thickening, 
fibrinoid necrosis and loss of VSMC. Similar changes are seen in CAA, where vessel 
deposits consist of beta-amyloid peptides. Chronic hypoperfusion with local hypoxia has 
been assumed to contribute to observed changes (39). Also increased permeability of the 
blood-brain barrier has been implicated (40), supported by the fact that lipohyalinosis 
contains fibrin and other plasma proteins. However, it has recently been questioned whether 
reduced cerebral blood flow is a cause or an effect of CSVD changes, as a longitudinal study 
found no association between baseline cerebral blood flow and WMC progression (41). Also, 
CSVD has been found to be a dynamic process, where lacunes, microbleeds and WMC may 
disappear in long-term follow-up (42). This has sparked speculation of underlying 
dysfunction in other cerebral structures or processes, such as the newly discovered 
glymphatic system for cerebral fluid transport (43) or the oligodendrocyte network (44). 
Studies on the role of platelets and CSVD are scarce and partly contradictory. Most studies 
suggest that platelet activation is more important in large vessel IS than small vessel IS (45). 
Oberheiden et al showed enhanced platelet activation in patients with CSVD as compared to 
healthy controls (46).  
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1.3 HEMOSTASIS AND THROMBOSIS – A PLATELET-CENTERED 
PERSPECTIVE 
Platelets are 2-5 µm anucleate cell fragments released into the circulation from 
megakaryocytes in the bone marrow. The normal platelet concentration in blood is 
approximately 150-400 x 109/l and the life-time in circulation 8-10 days. The primary 
function of platelets, together with the vessel wall and coagulation system, is to limit blood 
loss after vessel damage. A breach of the endothelial lining causes rapid and dramatic 
changes in platelet morphology and function. Aspects of platelet functions which are central 
to hemostasis and thrombosis are discussed below. The first two sections introduce platelet 
function according to the traditional model of hemostasis with primary and secondary 
hemostasis.  Section 1.3.3 discusses the role of MV in atherothrombosis, section 1.3.4 
addresses the advances in understanding the dynamic role of platelets in thrombosis and 
section 1.3.5 gives an overview of platelet function and cardiovascular risk factors.  
1.3.1 Platelets in primary hemostasis 
Under normal condition platelets circulate in an inactive, discoid shape. Healthy endothelial 
cells contribute to maintaining platelets inactive by releasing the platelet inhibitors nitric 
oxide (NO) and prostacyclin (PGI2) and expressing ectoADPase (CD39), which breaks down 
adenosine diphosphate (ADP), one of the main platelet agonists (see below). Endothelial 
damage leads to exposure of sub-endothelial proteins which bind platelet receptors (generally 
termed glycoprotein receptors, GP), causing platelet adhesion and activation. Under the flow 
conditions in arteries and arterioles, sub-endothelial collagen together with von Willebrand 
factor (VWF) are central for platelet adhesion (47). Exposed collagen binds circulating VWF, 
which subsequently binds the platelet receptor GPIbα of the GPIb-IX-V complex, see figure 
1. This leads to platelet tethering and translocation; firm adhesion involves binding of platelet 
GPVI and integrin α2β1 to collagen. Binding of these receptors causes platelet activation with 
stimulation of intracellular signal pathways and increased calcium concentrations. This leads 
to platelet cytoskeletal rearrangements with spreading and shape change, activation of the 
platelet receptor GPIIbIIIa through inside-out signaling, generation of thromboxane A2 
(TxA2) and degranulation of platelet granulae, see figure 1.  
GPIIbIIIa is the most abundant platelet receptor. Once activated, GPIIbIIIa can bind to 
several ligands. It stabilizes platelet adhesion to collagen via VWF. Further it supports 
platelet-platelet bonds via molecular bridges, primarily of soluble fibrinogen, but also fibrin, 
VWF and fibronectin can function as bridges (48). GPIIbIIIa is thus the central receptor for 
platelet aggregation. Binding of GPIIbIIIa to its ligands activates the receptor further, 
increasing platelet activation by outside-in signaling.  
Platelet activation causes degranulation, which contributes to the recruitment of platelets to 
the forming thrombus (49). Platelets contain two types of granules, α-granules and dense 
granules, where the former are most numerous.  
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Figure 1: Platelet adhesion and activation, simplified version based on (47). Platelet receptors with their main 
ligands: GPIb-IX-V binding VWF immobilized on collagen, integrin αIIbβ3 (GPIIbIIIa) binding fibrinogen and 
VWF, GPVI and integrin α2β1 binding collagen. Receptors signal via the kinases Src, Syk and PI 3 kinase 
(PI3K), which amongst other activates phospholipase Cγ (PLCγ ) generating the inositol-1,4,5-triphosphate (IP3) 
which stimulates calcium release from the dense tubular system (DTS). Laminin and its receptor integrin α6β1 
and the fibronectin receptor α5β1 have been omitted to limit complexity. Image by Jakob Svensson.   
 8 
α-granules contain a large number of proteins (more than 300), many related to adhesion, 
coagulation, anti-coagulation, fibrinolysis and wound healing. Importantly α-granules release 
VWF and fibrinogen, supporting platelet aggregation via GPIIbIIIa. Dense granules contain 
mainly non-protein small molecules, in particular ADP, adenosine tri-phosphate (ATP), 
calcium, magnesium and serotonin. In addition they contain polyphosphates. Both α-granules 
and dense granules carry membrane-bound platelet receptors such as GPIb-IX-V, GPVI and 
GPIIbIIIa, which are exposed on the platelet surface after degranulation, enhancing platelet 
adhesive properties. In addition, α-granules contain membrane bound P-selectin, which is 
only exposed on the platelet surface after α-granules release. P-selectin is thus a marker of 
platelet activation. P-selectin is important for platelet interactions with other cells, in 
particular leukocytes. 
Once the first layer of platelets has deposited over the sub-endothelium, platelet recruitment 
to the growing thrombus depends largely on the availability of soluble platelet agonists. The 
main soluble platelet agonists in vivo are thromboxane A2 (TxA2), ADP and thrombin (from 
the coagulation system). All of these signal via G-coupled receptors on the platelet (50). 
TxA2 is formed in activated platelets by several enzymes, see figure 1. Activated 
phospholipase A2 cleaves off arachidonic acid (AA) from the plasma membrane; AA is then 
converted to TxA2 by cyclooxygenase 1 (COX-1) and thromboxane synthetase. TxA2 
diffuses out of the platelet and activates thromboxane receptors on near-by platelets, signaling 
in an auto- and paracrine manner. TxA2 is a moderately strong platelet agonist, but has a 
short half-life (about 30 seconds) (50). ADP is released from dense bodies and may also be 
released from injured cells in the vessel wall. It activates the platelet purinerg receptors P2Y12 
and P2Y1 in an auto- and paracrine manner. ADP has an important role in amplifying the 
effect of other platelet agonists (50). Via P2Y12 ADP regulates overall platelet reactivity 
through inhibition of the enzyme adenylyl cyclase which generates cyclic AMP (cAMP). 
PGI2 from endothelial cells activates adenylyl cyclase, increasing cAMP levels, which acts as 
a general brake and suppresses platelet response to agonists. ADP stimulation of P2Y12 
counteracts the platelet inhibitory effect of PGI2, enhancing the response to other agonists. 
Thrombin is generated by the coagulation system and stimulates protease-activated receptors 
(PAR) on platelets, in humans PAR-1 and PAR-4. Thrombin also binds to GPIbα, which 
enhances platelet activation. Thrombin is a strong platelet agonist and higher concentrations 
cause a sustained increase of platelet calcium levels. In addition to the above agonists, 
platelets can be activated by circulating catecholamines, notably norepinephrine (51) but also 
epinephrine (50). Both signal primarily via the adrenerg α2A receptor on platelets (52), 
reducing cAMP levels, but likely also having other effects. On their own catecholamines are 
considered to be relatively weak agonists, but they potentiate the response to other agonists 
(50). Serotonin from dense granules is a relatively weak platelet agonist (53), which also 
potentiates the response to other agonists. It signals via the G-coupled receptor 5-HT2A in 
platelets and also has a vasoconstrictive effect.  
  9 
In addition to the above platelet receptors and agonists, platelet activation and aggregation 
depend on local flow conditions. In healthy arteries flow is laminar, with maximum flow 
velocity in the center and flow decreasing to zero at the vessel wall. The differences in flow 
velocities between neighboring fluid layers near the wall causes shear stress which exerts a 
pressure on flowing and adhering cells and molecules. Shear is generally measured as shear 
rate in the unit s-1. In veins and large arteries shear rate is generally low, about 500-1000 s-1, 
whereas in arterioles it can be up to 5000 s-1 and in stenotic arteries can reach levels ten times 
higher than in normal blood vessels (3, 47). Platelet aggregation under high shear rate 
depends critically on VWF binding to GPIb and GPIIbIIIa, which becomes more efficient as 
shear rate increases, likely due to increased exposure of VWF binding sites (54). Turbulent 
flow with rapidly varying shear can also cause platelet aggregation, independent of TxA2 and 
ADP signaling (54). While laminar flow will tend to wash out soluble platelet agonists, 
disturbed flow with eddies and vortices downstream of an arterial stenosis or thrombus can 
cause accumulation of soluble platelet agonists, maintaining platelet activation (47).  
Under the flow conditions in arteries and arterioles, the primary platelet plug cannot maintain 
stability for longer times and requires stabilization by fibrin fibers from the coagulation 
system, so-called secondary hemostasis.  
1.3.2  Platelets and secondary hemostasis  
The main component of secondary hemostasis is the coagulation system, consisting of a 
number of serine proteases and their co-factors which circulate in inactive form as zymogens. 
At vessel damage these are activated to produce thrombin which cleaves fibrinogen to 
fibrin. Fibrin molecules associate into fibrils which crosslink to form the fibrin network of 
blood clots. Coagulation is a powerful process which if activated systemically can have fatal 
consequences to the host. The coagulation system is therefore tightly regulated, amongst 
others by anticoagulant and fibrinolytic proteins.  
One of the primary functions of platelets in secondary hemostasis is to localize the 
coagulation process to the thrombus by anchoring coagulation factors to the surface of 
activated platelets, the so-called cell-based model of coagulation (55). On the activated 
platelet surface, coagulation factors assemble into coagulation complexes. These complexes 
generally consist of an enzyme, its co-factor(s) and the substrate being cleaved (56). Binding 
of coagulation complexes to the activated platelet surface increases their enzymatic efficiency 
by up to three orders of magnitude or more, substantially enhancing the amount of thrombin 
formed (56).  
The main coagulation complexes relevant to hemostasis and thrombosis are illustrated in 
figure 2 (56); coagulation factors are denoted f, the roman number and ‘a’ added for the 
activated form. At vessel damage, membrane bound TF is exposed on sub-endothelial cells 
and binds fVIIa, which is present in the circulation in low amounts. The resulting extrinsic 
tenase complex generates small amounts of fIXa and fXa which initiate coagulation. FXa 
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associates with fVa on activated platelets, forming the prothrombinase complex which 
cleaves prothrombin to thrombin (fII to fIIa). The small amount of thrombin generated during 
initiation activates fVIII and fXI; the latter in turn activates fIX. FIXa associates with its co-
factor fVIIIa to form the intrinsic tenase complex. The intrinsic tenase complex generates 
larger amounts of fXa and amplifies thrombin generation by the prothrombinase complex, so-
called propagation.  
 
 
Figure 2: The main coagulation complexes extrinsic tenase, intrinsic tenase and prothrombinase; also shown is 
the activation of fXI by thrombin (fIIa) and the subsequent activation of fIX by fXIa.. FIIa = thrombin. Image by 
Jakob Svensson. 
 
Thrombin is essential to the coagulation process not only as the final serine protease 
generating fibrin. It also activates several other coagulation factors: fV and fVIII, the 
necessary co-factors in the prothrombinase and tenase complexes, and fXI, which generates 
fIXa. In addition it activates fVII. Thrombin thus amplifies its own generation. Further, 
thrombin activates fXIII, which crosslinks fibrin fibers, forming the fibrin network. As 
mentioned above thrombin is also a strong platelet agonist. The prothrombotic roles of 
thrombin are illustrated in figure 3.  
In addition to the above complexes, coagulation can be initiated via the contact pathway, 
resulting in activation of fXII which activates fXI. As deficiency of contact pathway 
proteases in humans does not cause bleeding, the contact system is considered to have limited 
importance for hemostasis, but may be important in thrombosis, see section 1.3.4.5. 
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Figure 3: The different prothrombotic functions of thrombin (fIIa). Image by Jakob Svensson.  
 
Anticoagulant proteins restrict the coagulation process in time and space. Tissue factor 
pathway inhibitor (TFPI) inhibits the extrinsic tenase complex quickly, limiting its function to 
initiation of coagulation (56). Circulating antithrombin inactivates thrombin, fIXa, fXa, fXIa, 
fXIIa and possibly also fVIIa in the extrinsic tenase complex. Thrombin together with 
thrombomodulin activates protein C bound to endothelial protein C receptor on the surface of 
neighboring endothelial cells. Activated protein C (APC) then dissociates from the 
endothelial surface and associates with cofactors (among them protein S) on the activated 
platelet surface to cleave fVa and fVIIIa, inhibiting the intrinsic tenase and prothrombinase 
complexes (56). Thrombin thus has a self-limiting function. 
Activated platelets bind coagulation factors by different mechanisms. The vitamin K-
dependent coagulation factors (prothrombin, fVII, fIX and X) and  anticoagulants (protein C 
and protein S) contain a gamma-carboxyglutamic domain (Gla domain) which after 
activation and in the presence of calcium ions develops a hydrophobic patch, that allows 
incorporation into plasma membranes expressing negatively charged phospholipids. In 
resting platelets, as in other cells, an asymmetrical distribution of phospholipids is 
maintained, where the outer plasma membrane consists of neutral phosphatidylcholine and 
sphingomyelin and negatively charged phospholipids including phosphatidylserine (PS), 
phosphatidyl-etanolamine and phosphatidyl-inositol are found on the inner plasma membrane 
(57). This distribution is maintained by a balance of ATP-dependent aminophospholipid 
translocases, so-called flippase and floppase. Platelet activation, with elevated calcium 
concentration, inhibits flippase and activates floppase and scramblase, where the latter causes 
random transport of phospholipids across the membrane. This results in PS exposure on the 
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outer platelet membrane surface. (The platelet scramblase has recently been identified as 
TMEM16F (58).) PS binds the Gla domain of vitamin K-dependent coagulation factors and is 
thus a procoagulant factor of activated platelets. FV and fVIII contain different domains 
which allow binding to phospholipids of the plasma membrane, notably the C-domain. In 
addition, activated platelets have been shown to have specific binding sites for the 
coagulation factors of the intrinsic tenase and prothrombinase complex and fXI, in particular 
in their activated form (57). Both the binding affinity and enzyme complex efficiency can be 
higher after binding to activated platelets than after non-specific binding to PS on synthetic 
phospholipid vesicles (56, 57). Platelet expression of specific binding sites depend on the 
type and strength of platelet agonist stimulation, with thrombin combined with collagen 
having the strongest effect.  
In addition to anchoring the coagulation complexes, platelets contribute to and regulate 
coagulation in different ways. α-granules contain fibrinogen, fV and fXIII, and the presence 
of fVIII, fIX and fXI has also been reported (56). Degranulation increases the local 
concentration of these factors in the thrombus. Several granule proteins, including fibrinogen 
and fV are not synthesized by megakaryocytes, but taken up selectively from plasma by 
receptor-mediated, clathrin-dependent endocytosis in both megakaryocytes and platelets. FV 
is then ‘re-tailored’ creating platelet-derived fV which is distinct from plasma fV physically 
and functionally (56). Notably, platelet-derived fV is more readily activated, has higher co-
factor activity and is a poorer substrate for APC inactivation than its plasma counterpart (56). 
Furthermore, platelet fV in α-granules is partially activated at release, contributing to the 
initiation of coagulation as discussed above. Platelets also contain anticoagulants, among 
them antithrombin, TFPI and protein S as discussed above, but also others, such as protease 
nexin 1 and 2, where the former is a potent membrane-bound inhibitor of thrombin and the 
latter inactivates fXIa (57). In addition α-granules contain several proteins of the fibrinolytic 
systems, with both activating and inhibiting effects (49). Platelet activation can thus both 
promote and limit coagulation and fibrinolysis, and the regulation of these effects is unclear. 
Differential granule release may occur by different intracellular signaling pathways (59). α-
granules are heterogeneous in content, and it has been proposed that their release may be 
regulated differentially in time and space for an appropriate effect (60).  
1.3.3 Microvesicles in hemostasis and thrombosis 
1.3.3.1 History of microvesicles, general introduction 
In addition to platelets and coagulations factors, Chargaff and West in the 1940’s discovered 
a subcellular, sedimentable factor in plasma which could be removed by ultracentrifugation 
and supported thrombin generation (61). Wolf showed in 1967 that this factor consisted 
mainly of minute particles budding from platelets, which he termed ‘platelet dust’ (62). These 
particles were later called microparticles and the presently recommended term is 
microvesicles (MV) (63). MV have a diameter of 0.1-1.0 µm and are released from the 
plasma membrane at activation. Following Wolfs discovery it was found that MV can be 
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released from the plasma membrane of virtually all cell types at activation or apoptosis. MV 
form part of the larger group extracellular vesicles (EV) which also comprise the smaller 
exosomes (40-100 nm in diameter), released from intracellular multi-vesicular bodies, and the 
generally larger apoptotic bodies (64). The majority of circulating MV express 
platelet/megakaryocyte surface markers (65, 66). Erythrocytes, endothelial cells and 
leukocytes also release MV in the circulation, which can be identified by their respective 
specific surface markers (66).  
1.3.3.2 Platelet-derived microvesicles 
The majority of circulating MV carry platelet/megakaryocyte markers, and are termed 
platelet-derived MV (PMV). PMV are of importance for hemostasis and thrombosis in 
different ways. The procoagulant activity which led to their discovery is thought to be related 
partly to the expression of PS, which can bind coagulation factors as discussed above. MV 
expression of PS is considered connected to the mechanisms resulting in MV release (63) and 
PS has been shown to contribute substantially to MV capacity for thrombin generation (67). 
MV of non-platelet origin also express PS and can thereby contribute to coagulation. Notably, 
half or more of PMV in healthy volunteers do not express PS as identified by the PS marker 
annexin V (68, 69). In vitro generated PS-positive PMV bind coagulation factors fV, fVIII, 
fIX and fX with high affinity (70-73). In the latter study, PMV generated by calcium 
ionophore stimulation were estimated to be almost two orders of magnitude more 
procoagulant per surface area than activated platelets (73), indicating that coagulation factor 
binding sites can be enriched on PMV. Interestingly, in vitro generated PMV have also been 
shown to have anticoagulant effects (74). 
In addition to their effects on coagulation, PMV are of interest as markers of intravascular 
platelet activation. The half-life of MV in the circulation is limited and was found to be about 
five hours in humans (75). In particular PS-positive MV (PS+MV) bind different opsonins 
and are cleared by macrophages (76) or taken up by endothelial cells (77, 78). Despite this, 
PMV circulate in healthy at substantial concentrations (69), suggesting that MV expressing 
platelet surface markers are constitutively released. Flaumenhaft et al demonstrated that 
megakaryocytes can release PS+MV constitutively, which likely contribute to the circulating 
pool of MV identified as PMV (79). It has also been suggested that PMV may be released by 
aging platelets. However, even in healthy volunteers a subset of PMV express P-selectin 
indicating that they are released from activated platelets (79, 80). PMV levels have been 
found elevated in various pathological conditions related to platelet activation, including 
IS/TIA and AMI (63, 67, 80-82). It has been suggested that PMV expressing P-selectin could 
be more specific markers of platelet activation than overall PMV concentrations (83).  
The heterogeneity of PMV is increasingly recognized and depends on the circumstances 
leading to their release (76, 84). PMV can be generated by different types of stimulation: 
platelet agonists, inflammatory signals (e g lipopolysaccharide, immune complexes) or 
physical conditions (shear stress, hypoxia, storage) (76). The type and strength of stimulation 
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influence not only the amount of PMV generated but also their surface markers and 
cytoplasmic content (63). Once generated PMV can be taken up by various target cells, for 
instance endothelial cells, but also cells of the immune system (85). The effect of PMV on 
target cells also depends on their content and how they were generated.  
1.3.3.3 Tissue factor positive microvesicles 
As discussed above, TF is the main initiator of coagulation. In the cell-based model of 
hemostasis, TF was considered external to the circulation, coming into contact with blood 
only at vessel injury (55). In the ‘90’s several authors reported low concentrations of 
circulating TF in plasma and other body fluids (86, 87), but the results were questioned (88). 
However, in 1999, Giesen et al demonstrated that TF from human blood accumulated in 
experimental thrombi on pig arterial media and collagen-coated glass slides (89). Immuno-
electronmicroscopy identified TF-positive MV (TF+MV) in clusters near platelets. TF was 
shown to be functional, as blocking anti-TF-antibodies reduced the size of thrombi and fibrin 
formation substantially. TF+MV expressed the leukocyte marker CD18, and subsets of TF-
positive neutrophils and monocytes adhering to the thrombus were identified (89). TF+MV 
were estimated to be present in blood in sub-picomolar concentrations and TF was proposed 
to circulate ‘encrypted’, to be activated only in the microenvironment of the thrombus.  
Since their discovery, TF+MV have spurned research and debate (90-92). In line with the 
above study, Falati et al showed TF+MV accumulation in an in vivo mouse model of laser-
induced thrombosis, which lacked endothelial denudation (10). TF+MV bound to the 
thrombus via P-selectin glycoprotein 1 (PSGL-1) on MV and P-selectin on activated 
platelets. In the same study, TF+MV isolated from human blood expressed CD14, indicating 
monocyte lineage. Animal experiments suggested that also the generation of TF+MV 
depended on P-selectin stimulation of PSGL-1 on monocytes (93, 94). In contrast to the study 
by Falati, mouse models of vascular injury thrombosis with endothelial denudation showed 
no significant contribution from blood-borne TF or TF+MV to thrombus formation (95). The 
source of TF in circulating TF+MV has been debated, and neutrophils, platelets and 
endothelial cells have been proposed as alternative TF sources to monocytes (91). Monocyte-
derived TF+MV have been shown to bind to and fuse with activated platelets (96), which may 
explain the finding of circulating TF+MV expressing platelet markers (80, 97). Notably, the 
specificity of TF antibodies to identify TF on MV has been questioned (98). In addition to 
circulating TF+MV, atherosclerotic plaque contain TF+MV with active TF, which are highly 
procoagulant and thought to be derived from macrophages and VSMC (99). 
The mechanisms resulting in activation or ‘decryption’ of TF on TF+MV within a thrombus 
have not been unequivocally determined but may include PS exposure on platelets, 
modifications of disulfide bonds and/or conformational changes (100, 101). The clinical 
importance of circulating TF+MV in human thrombosis has not been fully clarified and may 
vary depending on pathophysiological conditions. However, TF+MV, in particular if 
combined with PS, may represent a circulating pool of important procoagulant potential.  
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1.3.4 Advances in the understanding of platelet function in thrombosis 
As illustrated by the discussion above, thrombus formation is a complex process, requiring 
dynamic coordination in time and space of the different elements of hemostasis with those of 
the injured vessel wall. In the last decades, improved molecular probes, microfluidic flow 
chambers and in vivo thrombosis models have clarified some of these interactions, sometimes 
with surprising results. Some important findings are summarized in this chapter.  
1.3.4.1 Dynamics of thrombus formation, alternative pathway for thrombus initiation 
The cell-based model of hemostasis was developed largely based on how isolated 
components of hemostasis behaved in vitro, viewing primary and secondary hemostasis as 
separate and partially sequential events. Ground-breaking work by the Furie group, using an 
in vivo mouse model with laser-induced thrombus formation in cremaster arterioles, 
illustrated how intimately platelets and coagulation interact to establish the thrombus, already 
from the earliest phase of thrombus initiation, summarized in (102). As this model did not 
include exposure of sub-endothelial structures, it suggested that alternative pathways for 
thrombus initiation were possible, including endothelial activation. Blood-borne TF+MV was 
shown to contribute to initiation of thrombin generation and thereby platelet activation as 
discussed above (10). TF accumulation and fibrin formation was shown start immediately 
after laser stimulation and increased over several minutes, while platelet accumulation 
occurred in two waves: a small one peaking at about 15-20 s and a larger one peaking after 1-
2 minutes. Platelet P-selectin started to increase only 2 minutes after thrombus initiation 
(103), and leucocyte adherence to the thrombus started after 2-3 minutes and peaked at 8 
minutes (104). Protein disulfide isomerase (PDI), a chaperone protein, was shown to be 
released from activated endothelial cells and platelets, and was found to be critical for 
thrombus formation in this model (10, 105). Recently circulating vitronectin has been 
identified as a PDI substrate; breaking of disulfide bridges in vitronectin allows binding to 
endothelial αvβ3, which is one of the earliest events in the laser-induced thrombosis model 
(106).  
1.3.4.2 Different platelet subpopulations 
Platelet activation in thrombosis was initially considered digital, with platelets being either 
activated or not. Research has shown that this is a simplified view and that platelets respond 
differently to different types of platelet activation and can adopt different ‘phenotypes’. The 
first evidence of this was found by Behnke in the ‘90’s. He identified two different platelet 
populations positive respectively negative for the enzyme phospho-tyrosine phosphatase 
(107). Platelets lacking the enzyme responded faster to thrombin and collagen stimulation and 
were the first to adhere after vessel injury (108). Heemskerk et al identified platelet 
populations positive respectively negative for PS, where the prevalence of PS exposure was 
enhanced by collagen and thrombin stimulation (109). The Dale-group subsequently 
identified a subpopulation of ‘coated’ platelets after platelet stimulation with thrombin and 
collagen, which expressed PS, bound fV and retained α-granule proteins on the platelet 
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surface (110, 111). Despite strong stimulation, only a proportion of platelets in healthy, on 
average 30%, adopted this phenotype. While healthy donors varied in the propensity to form 
coated platelets, this propensity was fairly stable over time in the same individual. Kempton 
et al using thrombin and convulxin also identified two platelet populations by flow 
cytometry, which differed in their ability to bind coagulation factors fV, fIX and fX (112).  
Combining flow cytometry, microfluidic flow cells and in vivo mouse models, Munnix et al 
could show that different platelet subpopulations formed also under physiological conditions 
(113). Two major platelet populations were identified: aggregating, PS-negative platelets, 
with only weak binding of coagulation factors fVa, fXa and prothrombin, and non-
aggregating, PS-positive platelets with strong binding of the same coagulation factors. 
(Coated platelets were a small minority of PS-positive platelets in these experiments.) The 
two populations separated in microdomains in thrombi, with PS-positive platelets developing 
a ‘ballooning’ morphology. Ex vivo experiments by Agbani et al also showed a population of 
PS-positive, ballooning, procoagulant platelets which were prone to microvesiculation, in 
contrast to spreading/aggregating PS-negative platelets (114). (They also observed two other 
platelet populations ex vivo.) In a follow-up study it was shown that platelet ballooning and 
PS-exposure were synchronized and could spread between platelets in platelet aggregates 
(115). Yakimenko in a mouse thrombosis model could show that PS-positive platelets were 
found close to the endothelium and in the thrombus core (116). While different authors have 
proposed other terms for PS-positive, procoagulant platelets, platelet procoagulance appears 
to be mediated largely by a subpopulation of platelets in thrombi (117). 
1.3.4.3 Discoid platelets in thrombus formation 
In addition to the above platelet phenotypes it has been found that discoid platelets associate 
reversibly to the outer surface of a forming thrombus (102). Shear-induced platelet 
aggregation can occur without irreversible platelet activation (118). Maxwell et al showed 
that adhesion of discoid platelets in vitro occurred via platelet membrane tethers (distinct 
from platelet filipodia) in a shear-dependent process (119). Tethering and platelet adhesions 
depended on GPIb and GPIIbIIIa binding to VWF. Reversible aggregates of discoid platelets 
formed under shear where discoid platelets would cover an activated, spread platelet. The 
process was independent of ADP, but ADP was central for converting unstable aggregates of 
discoid platelets to stable aggregates of activated platelets. It was proposed that an outer layer 
of aggregated discoid platelets could serve to protect the inner microenvironment of the 
thrombus from the effects of flow in the initial phases of thrombus formation. This would 
allow accumulation of soluble platelet agonists, enhancing platelet activation. It could also 
allow assembly of coagulation complex on activated platelets in the inner part of the 
thrombus, while restricting exposure of procoagulant surfaces to the bulk of the blood flow.  
1.3.4.4 Platelet interactions with other cells, neutrophil extracellular traps 
The extent of platelet interactions with other cells and the role of platelets in inflammation 
and atherosclerosis are increasingly recognized (8, 99). Activated platelets can interact with 
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leukocytes, in particular monocytes, neutrophils and lymphocytes, by platelet P-selectin 
binding to PSGL-1 on leukocytes or platelet CD40 ligand (CD40L) binding to leukocyte 
CD40. Platelets also express PSGL-1, whereby they can tether and roll on activated 
endothelial cells expressing P-selectin (after endothelial release of Weibel-Palade bodies). 
Subsequent cell adhesion involves additional binding of different adhesion molecules, 
including integrins, which activate both interacting cell types further. In these processes, 
platelets may release a number of proinflammatory chemokines, for instance PF4, NAP-2, 
MCP-1 and RANTES (8). Platelets can also be induced to synthesize IL-1β, amongst others 
by thrombin stimulation (120). In animal models of atherosclerosis, platelets and platelet-
leukocyte aggregates contributed to leukocyte recruitment to the endothelium, leukocyte 
activation and leukocyte transmigration (1, 2). Notably, several of the inflammatory functions 
of platelets can be mediated also by PMV, which can commute inflammatory signals 
remotely (85, 121). In humans it has not been verified that antiplatelet treatment reduces 
atherosclerosis, but circulating leukocyte-aggregates are increased in cardiovascular disease, 
suggesting that the above interactions have a role also in humans.  
In 2004, Brinkmann et al discovered a new form of neutrophil activation: Neutrophil 
Extracellular Traps (NETs) (122). On encountering pathogens, neutrophils decondensed their 
nuclear chromatin which mixed with granular contents. Chromatin strands decorated with 
antimicrobial enzymes and proteins were then released extracellularly. In infection, NETs 
were interpreted to limit dissemination of circulating pathogens. Since their discovery NETs 
have been found to play a role in various diseases and pathologies, including thrombosis 
(123). In sepsis, platelets stimulate NETosis via activation of the platelet TLR-4 receptor, 
expression of P-selectin and High Mobility Group protein B1 (124). If released in the 
circulation NETs are highly thrombogenic. They activate the contact pathway via factor XII, 
generating thrombin which leads to platelet activation (125). NETs also bind VWF and fibrin 
which contribute to platelet activation. Further, NETs may express TF (126), and NETs 
associated neutrophil elastase cleaves the anticoagulant TFPI (125). The importance of NETs 
for venous thrombosis is established (123), but NETs have also been found in arterial 
thrombosis, including acute IS (126-128). 
1.3.4.5 Platelet polyphosphates 
In 2004 it was discovered that phosphate was stored in dense granules in the form of 
polyphosphate chains of on average 70-75 phosphate groups (129). Dense bodies were 
proposed to be similar to acidocalcisomes of bacteria, which contain longer polyphosphates 
known to be procoagulant. Muller et al therefore studied platelet polyphosphates and found 
them to be procoagulant, which was claimed to be due to activation of fXII and the contact 
pathway (130). The latter claim was questioned and could not be reproduced in vitro as 
platelet sized polyphosphates induced only a weak activation of factor XII (131). Alternative 
procoagulant effects of platelet polyphosphates have been proposed, including enhanced 
activation of fV and fXI, and inhibition of TFPI (132). Recently, retention of polyphosphates 
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on activated platelet surface in form of nanoparticles were shown in vitro, which supported 
fXII activation (133). It is thus possible that the contact pathway contributes to thrombosis 
via platelet polyphosphates. In animal models of arterial and venous thrombosis, treatment 
with phosphatases was protective without increasing the risk of bleeding (134), supporting a 
role for platelet polyphosphates in thrombosis and suggesting that targeting polyphosphates 
could be a future treatment strategy.  
1.3.5 Cardiovascular risk factors and platelet function 
Certain cardiovascular risk factors may mediate risk in part by their effect on platelet 
function, with diabetes being the most notable example. The balance of platelet reactivity is 
governed by specific signal pathways, where in particular high cAMP and cGMP levels 
inhibit platelet activation, as illustrated in figure 4. Cardiovascular risk factors may disturb 
the balance in different ways; some of the mechanisms involved are discussed below. 
1.3.5.1 Diabetes, prediabetes and platelet function 
DM is known to increase platelet reactivity and a number of mechanisms are thought to be 
involved (135). Both chronic and acute hyperglycemia increase platelet activation. Platelets 
from patients with DM have higher expression of platelet activation markers and surface 
receptors than healthy controls (135). TxA2 synthesis is enhanced in type 2 DM (136). 
Several of the above changes are associated with HbA1c and respond positively to improved 
metabolic control. Acute hyperglycemia in type 2 DM enhances shear-induced platelet 
activation, with parallel increases in circulating VWF (54). Acute hyperglycemia also 
increases platelet sensitivity to agonists by different mechanisms: activation of protein kinase 
C, reduction of platelet NO synthesis and increased mobilization of calcium from intracellular 
stores, see figure 4 (135). Chronic hyperglycemia causes protein glycation with formation of 
advanced glycemic end products, AGEs. Glycation of platelet membrane proteins can 
influence protein function and decreases platelet membrane fluidity, which enhances platelet 
response to agonists.   
Type 2 DM and the metabolic syndrome are characterized by insulin resistance and high 
insulin levels in the early phase of disease. The effect of insulin on platelets is controversial. 
Platelets have insulin receptors, which inhibit platelets by increased cAMP levels, increased 
numbers of PGI2 receptors and influx of magnesium ions (135). Certain studies on healthy 
subjects found an inhibitory effect of insulin on platelet aggregation (137, 138). However, 
there are several studies showing the opposite effect, with insulin causing increased platelet 
aggregation, in particular for patients with obesity or diabetes (139-142). It has been proposed 
that platelets develop insulin resistance in a similar manner as other tissues (135). 
Interestingly, Vaidyula et al found that exposing healthy controls to simultaneously high 
glucose and high insulin levels by clamps increased platelet activation, monocyte TF 
expression and TF activity which resulted in enhanced basal thrombin generation (143, 144), 
suggesting a possible synergy of high glucose and high insulin levels on platelet function and 
hemostasis.  
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Figure 4: Schematic figure of factors that increase (red) and decrease (green) platelet reactivity. (Certain 
intracellular signaling pathways have been omitted to limit complexity). cAMP and cGMP are general inhibitors 
of platelet activation. cAMP signals primarily through protein kinase A (PKA) and cGMP via protein kinase G 
(PKG). These enzymes have various platelet inhibiting effects, amongst others limiting calcium mobilization 
(145). The healthy endothelium on the right releases prostacyclin (PGI2) which activates adenylyl cyclase (AC), 
increasing cAMP levels. It also releases nitric oxide (NO) which activates soluble guanylyl cyclase (sGC) 
forming cGMP. Endothelial dysfunction due to DM, hypertension or inflammation reduces endothelial 
generation of PGI2 and NO, increasing platelet reactivity. Oxidative stress inactivates NO. The catecolamines 
epinephrine and norepinephrine amongst others inhibit cAMP generation. Platelet inflammatory reactions can 
activate NAPDH oxidase 2 (NOX 2) (146), generating superoxide (O2-) which inactivates NO. Superdioxide 
dismutase (SOD) converts O2- to hydrogen peroxide (H2O2) which enhances calcium mobilization, increasing 
platelet reactivity (146). Ox-LDL binds the scavenger receptor CD36, which activates NOX2 and inactivates 
PKG (147). PDE: phosphodiesterases, enzymes that breakdown cAMP and cGMP. → : activating/stimulating 
effect; - -● : blocking/inhibiting effect. Image by Jakob Svensson.  
 
In addition to the above effects, patients with DM compared to healthy controls have higher 
platelet turnover, with higher proportion of recently formed, reticular platelets, known to be 
more reactive (135) . AGEs binding to the receptor for AGE (RAGE) on endothelial cells 
cause endothelial dysfunction with reduced release of NO and PGI2, which contribute to 
platelet hyper-reactivity (135), see figure 4. DM is also associated with dyslipidemia and 
inflammation which affect platelet reactivity (135), as discussed below.  
1.3.5.2 Dyslipidemia and platelet function 
Dyslipidemia is often seen in diabetes patients, with high triglycerides and low high-density 
lipoprotein (HDL). This attracted attention to how dyslipidemia may affect platelet function. 
Platelets express several lipoprotein receptors. Pedreno et al showed binding of LDL, VLDL 
and IDL to the platelet surface; in vitro LDL stimulated platelet aggregation to a similar 
degree as common platelet agonists (148). The platelet scavenger receptor CD36 binds 
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modified/oxidized lipids including glycated LDL and oxLDL, which causes platelet 
activation and aggregation, see figure 4 (147, 149). The lectin-like ox-LDL receptor 1 (LOX-
1) has similar effects (150). Notably, platelets can contribute to LDL oxidization via NAPDH 
oxidase 2 (150). High HDL levels reduce platelet aggregation, partly by cholesterol efflux 
mechanism in both platelets and endothelial cells, which cause platelet inhibition (151). 
Statin treatment also reduces platelet aggregation and PMV levels (67, 150).  
1.3.5.3 Inflammation, oxidative stress and platelet function 
As discussed in section 1.3.4.4, activated platelets can interact with leukocytes and 
endothelial cells and release proinflammatory substances. In the last decades, it has become 
clear that platelets should be considered inflammatory cells in their own right, linking 
hemostasis and immunity in both directions, and having the capacity to regulate 
inflammatory reactions (152). Platelets have a number of immunologic receptors including 
Toll-like receptors, complement receptors, cytokine receptors and receptors for the Fc domain 
of IgG and IgE (153). They have a repertoire of antimicrobial host defense mechanisms, 
including the ability to phagocytize smaller pathogens and can release antimicrobial peptides. 
Further, platelets can generate reactive oxygen species by NAPDH oxidase 2 (153), which is 
activated during platelet aggregation (146). Platelet thus contribute to oxidative stress and in 
turn superoxide enhances platelet aggregation response (154). Platelets interact with 
monocytes and neutrophils in inflammation, but notably also with different types of 
lymphocytes and dendritic cells, indicating that they can modulate also the adaptive immune 
response (155). Notably, these interactions may stimulate either pro- or anti-inflammatory 
responses. Platelets also regulate endothelial permeability under normal conditions and in 
inflammation (156). While the above platelet responses are adequate in for instance wound 
healing and infections, they likely contribute to enhanced platelet reactivity in chronic 
inflammatory conditions such as diabetes and systemic diseases.   
1.3.5.4 Hypertension and platelet function 
Hypertension is not considered to have direct influence on platelet function but involves 
endothelial dysfunction, which may lead to less efficient endothelial inhibition of platelets 
and enhanced platelet-endothelial interactions. Also, increased vessel stiffness could 
negatively influence shear and turbulence, which may contribute to platelet activation. 
Certain studies have found increased platelet sensitivity to agonists, altered NO availability 
and altered calcium metabolism in hypertensive patients, summarized in (157). 
1.4 MEASUREMENT OF PLATELET FUNCTION 
While hemostasis and thrombosis depend on interactions between circulating elements and 
the vessel wall, establishing the contributions of different components may be important in 
assessing the risk of thrombosis or bleeding. Early methods to assess platelet function 
included platelet counts and bleeding time; technological advances have led the development 
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of a number of methods that are more reliable and specific. A brief overview of some of the 
available techniques is given below. 
1.4.1 Light transmission aggregometry 
In light transmission aggregometry (LTA) or Born aggregometry, a platelet agonist is added 
to illuminated platelet-rich plasma (PRP) under stirring. As platelets aggregate, the light 
transmission through plasma increases, which is a measure of aggregation (158). The original 
light transmission is set to 0% and platelet-poor plasma (PPP) is set to 100% transmission; 
the measurement is thereby by definition individual and relative. LTA allows testing of 
different agonist and agonist concentrations, and it also gives a time profile for the platelet 
response. However, the method also has disadvantages. Testing has to be performed in close 
connection to blood sampling, and requires relatively large blood volumes if multiple 
agonists are to be tested. Testing is performed in the absence of other blood cells, 
centrifugation may result in loss of larger, more reactive platelets and the result depends 
platelet count. LTA requires expert knowledge and is relatively work intensive. Pre-analytical 
and analytical conditions are not standardized, making inter-laboratory comparisons difficult.  
LTA is by many considered the golden standard of platelet aggregation testing, and results 
correlate with risk of bleeding risk and thrombosis (158). Due to the disadvantages above, 
LTA is mainly used for investigations of specific platelet defects and in research.  
1.4.2 Flow cytometry methods 
In flow cytometry, cells or particles in suspension are guided through a narrow flow cell 
illuminated by lasers. When passing the interrogation aperture, cells scatter the light, allowing 
them to be counted individually. Scattering properties depend on cell size and internal 
granularity, allowing separation of different cell types. Labelling cells with fluorescent 
antibodies allows evaluation of specific surface markers. Flow cytometry of platelets can be 
performed in whole-blood, PRP or on washed platelets in suspension, all of which require 
analysis in relatively close connection to blood sampling. Gating strategies allows detailed 
investigation of specific subpopulations. Flow cytometry requires advanced laboratory 
equipment and specialist competence but is a powerful and versatile method. A wide range of 
antibodies allows the investigation of many aspects of platelet function; often simultaneous 
labelling with two or more antibodies is used. Some examples of platelet function aspects that 
can be studied with flow cytometry are discussed below.  
1.4.2.1 Platelet activation and reactivity 
Labelling of platelet surface markers expressed at activation allows evaluation of the degree 
of platelet activation under different circumstances or in response to platelet agonists. 
Common examples of activation markers include P-selectin, CD40L, activated GPIIbIIIa 
(labelled by the antibody PAC1), CD63 or surface-bound coagulation factors (159). 
Expression of platelet PS can be assessed by fluorescently labelled annexin V (and calcium) 
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or lactadherin (160). The output is often reported as percentage of platelets positive for a 
particular marker.  
1.4.2.2 Platelet-leukocyte aggregates 
A combination of scattering properties and expression of leukocyte-specific markers such as 
CD14 allows identification of specific leukocyte populations in blood, such as monocytes and 
neutrophils (159). The proportion of respective leukocyte population positive for platelet 
markers for instance GPIIb (CD41) can then be assessed.  
1.4.2.3 VASP-phosphorylation 
In addition to labelling platelet surface markers, platelets can be permeabilized in order to 
label intracellular antigens. This has led to the development of a specific application to assess 
the phosphorylation state of a protein down-stream of the P2Y12 receptor: vasodilator-
stimulated phosphoprotein (VASP). The degree of phosphorylation is a measure of P2Y12 
inhibition (159). A commercial kit of reagents and antibodies has been developed to simplify 
and standardize the measurement (BioCytex, Marseille, France).  
1.4.2.4 Microvesicles 
All the above measurements are performed on functional platelets/cells, which have to be 
analyzed in close connection to blood sampling. MV are present in plasma and can be 
analyzed by flow cytometry after one freeze-thaw cycle, allowing storage of samples. While 
sample handling for larger patient groups is easier, MV enumeration with flow cytometry is 
technically challenging (63). One aspect is the small size of PMV (median 200-300 nm) 
combined with a detection limit of flow cytometers, which is in the range half the wavelength 
of the exiting laser or more for scattering. Generally flow cytometers thus detect a minority of 
PMV, the so-called ‘tip-of-the-iceberg’ effect (161). Platelet activation may occur during or 
after blood-sampling, leading to spurious PMV release, which must be avoided or minimized 
(161). Other errors may occur, for instance swarm effects of smaller particles such as 
exosomes, protein aggregates, lipoproteins or aggregates of labelling antibodies (161).   
1.4.3 Whole blood aggregometry  
Whole-blood aggregometry (WBA) is an electric measurement, in which two electrodes are 
inserted into diluted whole-blood under stirring. After stimulation with an agonist, platelets 
adhere to and aggregate on the electrodes (158). This causes a change in the impedance 
between electrodes, which can be monitored. In the original Chrono-log instrument, cuvettes 
and electrodes were washed between measurements and re-used, limiting reproducibility. In 
multiple electrode aggregometry (MEA), disposable cuvettes with two electrode pairs per 
cuvette are used, resulting in a more reliable measurement (158). In MEA, impedance is 
tracked for six minutes and the area under the curve in arbitrary units is used as a measure of 
aggregation.  
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WBA by MEA has the advantage that it uses unprocessed, anticoagulated whole-blood 
diluted 1:1 with sodium-chloride solution. There is thus no influence of centrifugation, and all 
blood components are present. Different agonists can be tested, and the blood volume per 
cuvette is limited (300 µl). Limitations of the method include dependence on platelet count, 
hematocrit and temperature; further the results are influenced by the delay between blood-
sampling and analysis (158). While partly automatized, MEA requires pipetting and a certain 
amount of training. MEA is mainly used to evaluate response to antiplatelet treatment and 
bleeding risk. 
1.4.4 VerifyNow 
VerifyNow is a point-of-care optical method for whole-blood, which was developed 
primarily to evaluate response to antiplatelet treatment. Blood is inserted into cartridges 
containing fibrinogen-coated polystyrene beads and a platelet agonist; once activated platelets 
bind to and agglutinate the beads via GPIIbIIIa binding of fibrinogen (158). The increase in 
optical transmission due to agglutination depends the number of activated GPIIbIIIa receptors 
and platelet aggregation. Three types of cartridges with different agonists are available: one 
with AA, one with a combination of ADP and prostaglandin E1, and one with thrombin 
receptor-activating peptide (TRAP). The output for the first is reported as aspirin response 
units (ARU), for the second as P2Y12 units (PRU) and for the third as platelet aggregation 
units (PAU). Also the percent platelet inhibition of the first two cartridges relative to PAU is 
reported. (The TRAP cartridge is designed to give maximum platelet aggregation).  
VerifyNow has the advantage of being a true point-of-care method which is easily operated. 
It is standardized, allows direct comparison of results and is the most commonly used method 
to assess clopidogrel response. Limitations include a dependency on platelet count, 
hematocrit, triglyceride and fibrinogen levels. 
1.4.5 Other methods to assess platelet function 
The below methods are at present less common in large clinical research studies. Unless 
otherwise stated the information refers to (158). 
Plateletworks is a cell-counting technique which compares platelet counts in anticoagulated, 
mixed whole blood with and without the addition of a platelet agonist. It is easy to use and 
requires only limited instrumentation. 
Thromboelastography is based on the principle of increasing viscosity as blood clots. 
Anticoagulated whole blood is placed in a sample cup heated to 37oC which has a suspended 
rotating pin. After addition of a platelet agonist, blood starts to clot and the pin encounters 
increased movement inertia which can be measured. Several variables can be deduced from 
the output curve. The method has limited sensitivity for platelet defects and the effect of 
antiplatelet drugs.  
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The Platelet Function Analyzer 100/200 was developed to assess platelet aggregation under 
shear. Blood is aspirated through a tube 150 µm in diameter which contains an aperture 
membrane coated with collagen and epinephrine or collagen and ADP. The time to occlusion 
is a measure of shear-induced activation. The method has limited sensitivity and specificity, 
which has led to a decline in use.  
T-TAS is a new instrument for the study of platelet aggregation in whole blood in 
microfluidic capillaries where shear can be adjusted. The output is time to occlusion, and the 
evolution of the thrombus is documented by microscope (162). The capillary is coated with 
collagen or collagen and TF.  
P-selectin and CD40L are cleaved off from the platelet surface after activation and soluble P-
selectin and CD40L as measured by ELISA are sometimes used as markers of platelet 
activation.  
TxA2 is quickly metabolized in blood but the TxB2 metabolites are more stable and can be 
measured in blood or urine as an index of platelet TxA2 generation. Non-platelet generation 
of TxA2 limits the sensitivity.  
1.5 ANTIPLATELET TREATMENT AND RESPONSE  
1.5.1 Mechanisms of antiplatelet treatment 
1.5.1.1 Aspirin 
Aspirin inhibits COX-1 irreversibly by acetylation of the catalytic site, inhibiting platelet 
generation of TxA2 and thereby limiting platelet amplification and aggregation. Platelets do 
not synthesis of COX-1, and the enzyme therefore remains inhibited for the platelet life-time. 
Synthesis of prostacyclin in endothelial cells occurs both via COX-1 and COX-2. Low-dose 
aspirin treatment only marginally affects endothelial prostacyclin synthesis, resulting in a 
clear net platelet inhibiting effect. High-dose aspirin inhibits also COX-2, but endothelial 
cells can resynthesize the enzyme. Selective COX-2 inhibitors can shift the 
TxA2/prostacyclin balance, which may be one explanation for the increased risk of 
thrombosis seen for selective COX-2 inhibitors. 
1.5.1.2 P2Y12 receptor inhibitors 
The first P2Y12 receptor inhibitors ticlopidine and clopidogrel are structurally related 
thienopyridines. Both are prodrugs, which are metabolized into their respective active 
metabolites in the liver. Ticlopidine has largely been abandoned due to unacceptable side 
effects. Clopidogrel is for the most part hydrolyzed by hepatic carboxylases into an inactive 
metabolite (85-90%). The remaining 10-15% are metabolized by cytochrome P450 enzymes 
in two steps to form the instable, short-lived active metabolite R-130964 (163). R-130964 
encounters platelets in the hepatic circulation and inhibits the P2Y12 receptor irreversibly. 
Under maintenance treatment with 75 mg/day, platelet inhibition increases incrementally 
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reaching a plateau after 4-5 days (164). After a loading dose of 300-600 mg clopidogrel, 
platelet inhibition can be demonstrated after 2-5 hours.  
Both ticlopidine and clopidogrel have been reported to have ‘off target effects’, which 
include a reduction of fibrinogen levels, reduced erythrocyte aggregation, enhanced NO 
production and reduced TF expression in endothelial cells which may contribute to their 
antithrombotic effect (164).  
The relatively long response time and large individual variations in platelet response to 
clopidogrel (see section 1.5.2.2) have prompted the development of more effective P2Y12 
receptor inhibitors for ACS. Prasugrel is a thienopyridine metabolized more effectively than 
clopidogrel as metabolization starts in the intestine. The time of onset is therefore quicker and 
platelet inhibition more uniform than for clopidogrel (164). Cangrelor is an ATP-analogue 
which is not broken down by circulating ectonucleotidases. It is administered intravenously, 
has a short half-life and reversibly inhibits the P2Y12 receptor (164). Ticagrelor is an oral 
reversible inhibitor of the P2Y12 receptor, with a binding site different from the ADP binding 
site. Ticagrelor also inhibits the equilibrative nucleoside transporter 1 (ENT-1), increasing 
adenosine levels (165). In clinical studies on ACS, prasugrel and ticagrelor compared to 
clopidogrel have enhanced platelet inhibition and improved clinical outcome at the cost of 
increased bleeding risk (166, 167).  
1.5.1.3 Dipyridamole, cilastozol  
Dipyridamole was developed as a vasodilator in the 1960’s, and its antithrombotic effect has 
emerged during clinical use. Its working mechanisms are diverse and are not restricted to 
platelets but involve different cells in the circulation. Dipyridamole inhibits the adenosine 
transporter, primarily in erythrocytes, resulting in increased adenosine concentrations and 
longer adenosine half-life in the circulation (168). Adenosine binding to platelet adenosine 
receptors stimulates adenylyl cyclase, which increases platelet cAMP levels and cause 
platelet inhibition. Dipyridamole also inhibits the breakdown of platelet inhibitory cAMP and 
cGMP by inhibiting platelet phosphodiesterases (PDE), in particular PDE5, which can 
potentiate the platelet inhibiting effect of endothelial NO and PGI2. Further, dipyridamole 
stimulates endothelial PGI2 production (168). Dipyridamole in combination with aspirin 
reduces the number of PAR-1 receptors on platelets, suggesting that it can modulate platelet 
response to thrombin. It has antioxidant and anti-inflammatory effect including reduced 
superdioxide generation by neutrophils, reduced lipid peroxidation and reduced oxidation of 
LDL (168). It inhibits VSMC proliferation after vessel injury and reduces thrombus 
formation in in vivo models. Finally, dipyridamole appears to improve microvascular 
circulation and resistance to ischemia. It does not increase bleeding in large studies, however, 
it has a number of side effects including headache. 
Cilostazol is a selective, reversible PDE3 inhibitor which limits the break-down of platelet 
cAMP, resulting in a general platelet inhibiting effect (169). In addition it has been found to 
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reduce triglyceride levels and increase HDL. In Sweden it is only approved for treatment of 
peripheral artery disease, but it is used for stroke prevention in Asia (170). It has a number of 
side effect, including increased mortality in patients with heart failure, but does not appear to 
increase bleeding.  
1.5.1.4 GPIIbIIIa inhibitors 
As GPIIbIIIa is the central receptor for platelet aggregation, it is an attractive target for 
antiplatelet treatment. Three intravenous treatments have been developed and are mainly used 
for short-term treatment in connection with percutaneous coronary intervention (PCI): the 
antibody abciximab and the low molecular weight molecules tirofiban and eptifibatide. 
Abciximab binds and inhibits also integrin αvβ3 on endothelial cells, VSMC and platelets as 
well as αMβ2 on leukocytes, thereby inhibiting platelet interactions with the endothelium and 
leukocytes (171).  
Oral GPIIbIIIa inhibitors were developed and tested in large scale studies but were found to 
increase bleeding and mortality (172). 
1.5.1.5 Other platelet inhibitors  
The platelet TxA2 receptor inhibitor terutroban was tested versus aspirin for patients with IS 
or TIA, but the result was neutral (173). 
Vorapaxar is an antagonist of the thrombin receptor PAR-1. Vorapaxar in addition to 
clopidogrel for patients with ACS gave borderline significance for improved effect but also 
increased bleeding rates, in particular intracranial bleeding (174).  
1.5.2 High on-treatment platelet reactivity 
It is well-known that there are individual variations in both baseline platelet function and 
platelet aggregation response to antiplatelet treatment. Seminal work by Helgason et al in the 
early nineties showed that incomplete inhibition of platelet aggregation by aspirin as 
measured by LTA was not uncommon in patients with acute or previous IS (175, 176). The 
authors proposed that certain patients should be considered biologically ‘aspirin resistant’. 
Similarly, Järemo et al in 2002 showed large inter-individual variations in the response to 
loading dose of clopidogrel in patients with stable angina pectoris the day after PCI (177). 
These findings were confirmed in a larger study by Gurbel et al, who found marked 
individual variation in clopidogrel response also after 30 days of treatment, with 15% of 
patients remaining ‘clopidogrel resistant’ (178). These pioneering studies have led to the 
development of the term ‘high on-treatment platelet reactivity’ (HPR): high residual platelet 
aggregation in vitro despite antiplatelet treatment.  
While HPR has been a fruitful scientific concept to discuss platelet response to treatment, it 
has limitations. Firstly, HPR should not be interpreted as lack of therapeutic effect. 
Atherothrombosis is a highly complex process, and targeting the platelet, which is only one 
component, cannot be expected to eliminate the risk of recurrent ischemic events. Overall, 
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single antiplatelet therapy reduces the risk of a new vascular event in patients with CVD by 
22% (179), i e recurrences can be expected without HPR. Secondly, HPR concerns in vitro 
platelet aggregation, which is an artificial event. As discussed above platelet function can be 
measured by different techniques, with different agonists, and different cut-offs have been 
used to define ‘high residual platelet aggregation’. Considering the varying measurement 
conditions of the above methods (whole-blood versus PRP, centrifugation or not, flow 
conditions, anticoagulants, contact surfaces et cetera) it is not surprising that there is limited 
correlation between methods in identifying patients with HPR (180, 181). To limit these 
effects it has been agreed to evaluate HPR relative to the platelet signal pathway inhibited, i e 
stimulated by AA for the effect of aspirin and by ADP for the effect of P2Y12 receptor 
inhibitors (182).  
Despite the above limitations, meta-analyses indicate that HPR, as established by different 
measurement methods, is a clinically important phenomenon. Krasopoulos et al found HPR 
to aspirin to be associated with increased OR of CVD event (OR 3.85), ACS (OR 4.06) and 
death (OR 5.99) in 2 930 patients from 20 studies, 28% of which were classified as ‘aspirin 
resistant’ (183). Similarly Aradi found patients with HPR under clopidogrel treatment to have 
increased risk of AMI (OR 3.00), CVD event (OR 4.95) and cardiovascular death (OR 3.35) 
in a meta-analysis of 9 187 patients, where 33% had HPR (184). These OR’s are remarkably 
high considering an expected maximum treatment effect of 30%; not taking the drug at all 
would statistically result in a relative risk (RR) of at most 1.5 if patients were otherwise 
comparable (185). The existence of a generally ‘hypo-responsive’ or globally hyper-reactive 
platelet phenotype has been proposed to explain the high OR’s (182, 186), but selection and 
publication bias cannot be excluded.  
As the pharmacodynamic and pharmacokinetic aspects of HPR to aspirin and P2Y12 receptor 
inhibitors vary, they will be discussed separately.  
1.5.2.1 HPR to aspirin 
In healthy persons, aspirin results in a near complete inhibition of COX-1, and HPR to 
aspirin, interpreted as inability of aspirin to inhibit its target COX-1 is rare. However, platelet 
TxA2 synthesis under aspirin treatment may occur by various mechanisms. Full TxA2 
suppression requires 97% inhibition of COX-1 (185) and a residual COX-1 activity of 10% is 
sufficient to generate TxA2-induced platelet aggregation (163). Platelets released 12-24 hours 
after aspirin intake may have COX-1 activity and they also express some COX-2 which can 
generate TxA2 (163). High platelet turnover, as is seen for instance in DM, with a higher than 
normal proportion of newly formed platelets increases the risk of HPR to aspirin (187). Drug 
interactions can also influence aspirin response. PPI reduces aspirin bioavailability and 
NSAID such as ibuprofen and naproxen competitively but reversibly bind COX-1, limiting 
the effect of aspirin (187). In inflammatory conditions, COX-2 in endothelial cells and 
monocytes may generate prostaglandin H2 which can be transferred to platelets via cell-cell 
interactions and there be converted into TxA2 by thromboxane synthase independently of 
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COX-1 (163). Shear-induced platelet activation is known to be insensitive to ASA treatment 
(188). Finally, compliance is always a possible explanation for HPR. In one study comparing 
platelet aggregation under self-reported maintenance treatment with low dose aspirin with 
aggregation two hours after witnessed intake of 325 mg aspirin, the prevalence of HPR 
dropped from 9% to less than 1% (one patient out of 190) (189).  
Increasing the aspirin dose can reduce the proportion of patients with HPR to aspirin but has 
so far not been found to improve outcome and increases the risk of bleeding. As true HPR to 
aspirin is rare, platelet function tests are presently not recommended (7). It is possible that 
HPR to aspirin should be considered a non-modifiable risk marker. Changing to dosage to 
twice daily may both reduce the prevalence of HPR and improve outcome in patients with 
high platelet turnover such as diabetes, but has so far not been implemented in the clinic.  
1.5.2.2 HPR to ADP  
Most of the insights on HPR to ADP are based on studies on clopidogrel in patients with 
ACS and/or patients treated with PCI. The recommended measurement techniques and their 
respective cut-off limits have been agreed in a consensus document (182).  
Given the complex metabolism of clopidogrel, platelet aggregation response variability has 
been considered to depend largely on variable and insufficient generation of the active 
metabolite (182). A significant effort has been devoted to clarify clopidogrel absorption, 
hepatic metabolism, drug interactions et cetera. This has led to the discovery genetic 
polymorphisms, in particular for cytochrome P450 (CYP) enzymes. The CYP2C19 loss of 
function allele CYP2C19*2 has attracted particular interest (163). CYP2C19 is involved in 
both steps of clopidogrel activation and is associated with HPR to ADP (190). Despite a high 
heritability of HPR to ADP under clopidogrel treatment, the CYP2C19*2 allele was found to 
explain on 12% of the variation in ADP-induced aggregation (191). Notably, in the 
CHARISMA trial, CYP2C19 variants resulting in poor metabolization of clopidogrel were 
not associated with higher risk of primary outcome in the treatment arm but overall poor 
metabolizers had higher risk, independent of clopidogrel treatment (192).  
Several CYP enzymes involved in clopidogrel metabolism are susceptible to drug 
interactions or enzyme induction by other substances. Thus proton pump inhibitors, lipophilic 
statins and calcium channel blockers compete with clopidogrel for metabolization by 
CYP2C19 and CYP3A4, and ex vivo tests have shown a reduced platelet response to 
clopidogrel under co-medication (182). However, these interactions appear to have a limited 
or no effect on clinical outcome (193). St John’s wort, smoking and rifampicin stimulate 
enzyme activity of CYP1A3 and CYP3A4, enhancing clopidogrel metabolism. Clinical 
variables have also been associated with HPR to ADP under clopidogrel treatment, most 
consistently age, DM, high BMI, chronic kidney disease, ACS and PCI (163). 
The improved clinical effects of prasugrel and ticagrelor compared to clopidogrel for ACS 
patients suggest that HPR to ADP and its associated risk can be overcome (166, 167). 
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However, studies on platelet function guided adjustment of antiplatelet therapy in patients 
with HPR have so far been negative (7, 194, 195). In addition, certain patients have a strongly 
suppressed platelet aggregation response to P2Y12 inhibitors, so-called low on-treatment 
platelet reactivity (LPR), which is associated with increased risk of bleeding (7, 196). It has 
been proposed that there is a ‘therapeutic window’ of platelet response to ADP where the risk 
of both ischemic events and bleeding are low, so-called optimal platelet reactivity (OPR) 
(197).   
1.6 PLATELET FUNCTION AND ANTIPLATELET TREATMENT IN ISCHEMIC 
STROKE 
1.6.1 Platelet function in ischemic stroke 
There is ample evidence for a role of platelet activation in IS. Elevated levels of platelet 
activation markers PF4 and β-thromboglobulin have been found in several studies on patients 
with IS, summarized in (198). Platelet activation as measured by flow cytometry has also 
been found elevated in several studies. Grau et al found higher proportion of platelets 
expressing P-selectin and CD63 in patients with acute IS as compared to healthy controls; 
levels remained elevated also in the chronic phase (199). Zeller et al found elevated levels of 
platelets expressing P-selectin, CD63 and thrombospondin in acute IS caused by 
atherosclerosis, but not in cardioembolic IS (200).  Meiklejohn et al found increased platelet 
expression of P-selectin and platelet fibrinogen binding in patients with acute non-
cardioembolic IS, and levels remained elevated three months after symptoms (201). Garlichs 
et al found elevated platelet expression of P-selectin and CD40L and soluble CD40L in the 
acute phase of IS or TIA compared to matched controls, as well as higher levels of platelet-
monocyte aggregates (202). Levels remained elevated three months after symptoms, and 
notably differences were small between patients with IS and TIA, and also between different 
IS subtypes.  
In animal models, the extent of cerebral infarction depends on secondary platelet activation in 
ischemic cerebral microvessels (198). In a model of photo-induced IS, infarct size was 
reduced by blocking platelet GPIb and GPVI, but not GPIIbIIIa, where inhibition instead 
caused infarct hemorrhage (203). Microvascular occlusions after IS contain platelets, fibrin 
and typically neutrophils (198). Early platelet adhesion and activation in the ischemic 
microvasculature are thought to contribute to ‘no reflow’ and reperfusion injury after IS 
(204). In humans, a phase III trial of abciximab for acute stroke was abandoned due to lack of 
efficacy and increased risk of bleeding (205). 
While the role of platelet activation and the preventive effect of antiplatelet treatment are 
established in IS, maintained platelet function reduces the risk of hemorrhagic transformation 
of IS, which is a common and sometimes symptomatic complication (198).   
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1.6.2 High on-treatment platelet reactivity in ischemic stroke 
HPR, in particular to ADP, has been less studied for IS than for ACS. In addition, there is less 
agreement in the stroke community on HPR definitions, cut-off levels, optimal timing of 
measurement and so forth. Lim et al reviewed platelet function studies in stroke and reported 
varying prevalence of HPR in patients with IS/TIA, largely depending on differences in 
measurement techniques and HPR definitions (206). A recent meta-analysis of 8 364 patients 
with IS/TIA in 52 studies evaluated the prevalence of HPR to aspirin respectively to ADP 
under clopidogrel treatment, and found HPR in 23% of patients treated with aspirin and in 
27% of clopidogrel treated patients (207). A minority was treated with clopidogrel (1 783 
patients) and there was significant heterogeneity between studies. Outcome was analyzed in 
18 of the 52 studies and showed HPR to be associated with a significantly increased risk of 
recurrent IS/TIA, RR 1.81, p < 0.001, again with important heterogeneity. Numerically the 
relative risk was somewhat higher in clopidogrel treated patients, but the difference was not 
significant. In a large meta-analysis by Taglieri et al, HPR to ADP under clopidogrel and 
aspirin treatment in patients treated with PCI was associated with increased risk of stroke 
during follow-up, RR 1.84 (208), supporting the notion that HPR is clinically important for 
stroke. 
There are no randomized studies on platelet function guided adjustment of antiplatelet 
therapy in patients with IS/TIA, but certain findings should be mentioned. Depta et al 
investigated outcome in a retrospective, observational study of IS/TIA patients referred to 
LTA measurement by their responsible physician (209). The majority of patients were treated 
for a recurrent event and several had dual antiplatelet treatment at the time of testing. HPR to 
aspirin was seen in 43% of patients on aspirin treatment, HPR to clopidogrel in 35% and 
HPR to both aspirin and clopidogrel in 19% of patients on dual anti-platelet treatment. Based 
on the results, anti-platelet treatment was intensified in 23% of patients, either by dose 
increase, adding an additional antiplatelet agent or switching to a more potent anti-platelet 
agent as decided by the responsible physician. Patients with intensified treatment had higher 
risk of the composite endpoint death, new ischemic event or bleeding when analyzing the 
data with propensity score matching (HR 2.24, p=0.02). In univariate analysis intensified 
treatment resulted in both higher rates of ‘any bleeding’ and ‘recurrent IS/TIA’. While there 
are likely selection effects, the study illustrates the complexity of intensified antiplatelet 
treatment in patients with IS/TIA. In another observational study, Maruyama et al studied 
prevalence of HPR to ADP as measured by VerifyNow in IS patients treated with 
clopidogrel, cilostazol or a combination of the two. The combination cilostazol and 
clopidogrel had low HPR prevalence, less than 3% as compared to 25% for clopidogrel (210). 
Outcome was not assessed.  
In summary, the prevalence of HPR in patients with IS/TIA appears to be similar to that 
found in patients with ACS and confers an increased risk of recurrent IS/TIA. Whether 
intensified platelet inhibition can reduce the risk without increasing bleeding remains to be 
demonstrated. 
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1.6.3 Antiplatelet treatment for ischemic stroke and TIA  
The protective effect of antiplatelet therapy against CVD is established since the 1990’s. In 
the updated meta-analysis from the Antithrombotic Trialists’ Collaboration, antiplatelet 
therapy in patients with previous IS or TIA reduced the risk of a new cardiovascular event by 
22% compared to placebo (179). The risk reduction for short term treatment after acute IS 
was 11%. Subsequent studies have compared antiplatelet treatment with each other rather 
than placebo.  
A summary of the large antiplatelet trials comparting antiplatelet treatments for IS is given in 
table 1. Most early studies had a postponed randomization in relation to the index event to 
avoid hemorrhagic transformation/ICH. In spite of this, dual antiplatelet therapy with aspirin 
and clopidogrel compared with aspirin gave negative results in the MATCH trial, with no 
significant protective effect and increased risk of life-threatening bleeding (4). The SPS3 
study on patients with lacunar infarcts, (primarily due to CSVD) gave similar results, 
showing that clopidogrel in addition to aspirin increased both bleeding and mortality (5). 
CAPRIE compared aspirin to clopidogrel, finding no significant difference in patients with IS 
(211). The combination of aspirin with dipyridamole compared to aspirin alone was studied 
in ESPS-2 and ESPRIT, showing a clear added protective effect without increased bleeding 
as compared to aspirin (212, 213). However, the PROFESS study could show no advantage 
of combined aspirin/dipyridamole compared to clopidogrel in monotherapy (13), and in fact 
the bleeding rate was marginally higher in the aspirin/dipyridamole arm. Importantly, the 
discontinuation rate was higher for aspirin/dipyridamole than clopidogrel in PROFESS, 
which was also noted in ESPRIT (213).  
More recent studies have focused on reducing recurrent IS in the first months after IS/TIA, 
when the relative risk per time unit is the highest. The CHANCE trial found that early dual 
antiplatelet treatment with aspirin and clopidogrel in the first three weeks after IS/TIA could 
improve outcome without increased risk of bleeding (214). The cohort was Chinese, 
relatively young (average 62 years) and had high rates of smoking (> 40%), which gave rise 
to questions of external validity. The SOCRATES trial did not show a significant benefit of 
ticagrelor over aspirin in the first three months after IS/TIA, but also no increase in bleeding 
(215). The recent TARDIS trial compared triple therapy (aspirin, clopidogrel and 
dipyridamole) with guideline recommended treatment (clopidogrel monotherapy or 
aspirin/dipyridamole) (216). The study was terminated prematurely due to excess bleeding in 
the triple therapy arm, emphasizing the risks of intensified antiplatelet treatment in the 
acute/subacute phase of IS/TIA. 
Considering the high risk of recurrence in the first weeks and months after IS/TIA, Rothwell 
et al in a meta-analysis analyzed the effects of early aspirin treatment and the added effect of 
dipyridamole from previous placebo-controlled studies (217). They could show that aspirin 
strongly reduced both the incidence (HR 0.42) and severity of recurrent IS in the first six 
weeks of treatment but also between six and twelve weeks. Notably, there was no significant 
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effect of aspirin versus control after twelve weeks. Dipyridamole did not have an additive 
effect in the first twelve weeks but did reduce risk after twelve weeks (OR 0.72). Notably, in 
ESPRIT the added benefit of dipyridamole to aspirin was apparent only after about two years 
(213). The optimal timing of antiplatelet treatment as well as the delay until treatment effect 
may differ between antiplatelet agents. 
 
Study Intervention Nr patients 
Rx 
timepoint 
Follow-up 
time Outcome RRR 
AR diff 
bleeding 
ESPS-2 
1996 
Asp vs placebo 
6 602 < 3 mo 24 mo Recurrent stroke 
-21% +1.7% 
Dp vs placebo -19% ns 
Asp+Dp vs 
placebo -41% +1.9% 
      
CAPRIE* 
1996 Clo vs Asp 6 431 ’Recent’ 1.9 y 
Recurrent 
IS, AMI, 
vasc death 
NS 
NS 
(-7%) 
MATCH 
2004 Asp+clo vs clo 7 599 < 3 mo 18 mo 
Recurrent 
ischemic 
event 
NS 
+1.3% 
(-6%) 
ESPRIT 
2006 Asp+Dp vs Asp   2 739 < 6 mo 3.5 y 
Recurrent 
stroke, AMI, 
CVD death, 
major bleed 
-20% -1.3% 
PROFESS 
2008 Asp+DP vs clo 20 332 < 4 mo 2.5 y 
Recurrent 
IS NS +0.5% 
SPS3       
2012 Asp+clo vs Asp 3 020 
< 6 mo 
3.4 y Recurrent stroke 
NS  
+1%/y 
> 2 we (-8%) 
CHANCE 
2013 
Acute Clo+Asp 
vs Asp 5 170 < 24 h 3 mo 
Recurrent 
stroke -32% NS 
SOCRATES 
2016 Ticagr vs Asp 13 199 < 24 h 3 mo 
Recurrent 
stroke, AMI, 
death 
NS 
NS 
(-11%) 
 
TARDIS** 
2018 
Asp+Clo+Dp vs 
Asp+Dp or C 3 096 < 48 h 1 mo 
Recurrent 
stroke or 
TIA 
NS 
2% 
(-10%) 
 
Table 1 Summary of large randomized controlled trials comparing antiplatelet treatment for patients with 
ischemic stroke (IS) or TIA. Nr patients: number of patients in trial; Rx timepoint: timepoint of randomization 
relative to index event; RRR: relative risk reduction for primary outcome; AR diff bleeding: absolute risk 
difference for major or fatal bleeding; Asp: aspirin; Dp: dipyridamole; clo: clopidogrel; Ticagr: ticagrelor. *) 
Stroke subgroup of CAPRIE study, **) TARDIS was interrupted due to bleeding complications. (4, 5, 13, 212-
216) 
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The effect of antiplatelet treatment may also depend on IS subtype, and in particular patients 
with large vessel disease can be expected to benefit from intensive antiplatelet treatment. A 
subgroup analysis of the SOCRATES trial investigating patients with ipsilateral extra- or 
intracranial stenosis showed significant reduction of stroke, AMI or death with ticagrelor as 
compared aspirin, HR 0.68 (218). 
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2 AIMS 
The overall aim of this thesis was to investigate platelet function and response to antiplatelet 
treatment in patients with ischemic stroke (IS) or TIA. This included in particular study of 
High on-treatment Platelet Reactivity (HPR) to clopidogrel and microvesicles (MV) in 
IS/TIA cohorts. A further aim was to assess thrombin generation variables and their relation 
to platelet function in patients with IS/TIA, since thrombin 1) is a strong platelet agonist 2) 
links platelets with coagulation and 3) is a measure of coagulant activity/potential. Thus, the 
specific aims of the studies in the thesis were: 
• To determine the prevalence of HPR under clopidogrel treatment in patients with IS 
or TIA (Study 1 and 2). 
• To investigate the association between HPR to clopidogrel and clinical variables in 
patients with IS or TIA, with particular emphasis on: 
o Disturbances in glucose metabolism (study 1). 
o Ischemic stroke subtype and presence of large artery atherosclerosis 
respectively cerebral small vessel disease (CSVD) (study 2). 
• To investigate platelet microvesicles (PMV), thrombin generation variables and 
microvesicle-induced thrombin generation in patients with IS or TIA, and the 
association between these variables and future cardiovascular complications (study 3 
and 4). 
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3 METHODS 
3.1 STUDY POPULATIONS AND STUDY DESIGN 
3.1.1 Study 1 and 2 
Study 1 and 2 were cross-sectional studies, investigating prevalence of HPR under 
clopidogrel treatment one month after IS/TIA, and associations between HPR and clinical 
variables. Patients were selected from the StrokeDiabetes study at Danderyd Hospital 
(Clinical Trials NTC 01648985), which recruited 144 patients with minor IS or TIA between 
2010 and 2012 for the study of glucose metabolism, platelet function and life-style factors. 
Patients of study 1 and 2 were those receiving clopidogrel as secondary prevention and were 
still on this treatment at the one month control, in total 66 patients for study 1 (recruited until 
end of 2011) and 72 patients for study 2 (after completed recruitment). Inclusion criteria were 
acute minor IS/TIA and susceptibility to life-style changes. Exclusion criteria were inability 
to perform oral glucose tolerance test (OGTT) and estimated life expectancy less than one 
year. Between study 1 and study 2 five patients were excluded (two due to dual antiplatelet 
treatment with aspirin and clopidogrel, two due to platelet aggregation tests only being 
available from the subacute phase and one due to final diagnosis other than IS or TIA); 61 
patients were thus common to study 1 and 2. Patients were recruited median 2 days after 
symptoms (range 0-19 days) and were evaluated at the one month control median 34 days 
after symptoms (range 20-51 days). 
3.1.2 Study 3 and 4 
Study 3 and 4 were cohort studies. The cohort was recruited 2007-2009 at two stroke centers 
in Stockholm (Danderyd Hospital and Södersjukhuset) within the Proppstopp study. The 
original study had two objectives: 1) to screen patients with IS/TIA for occult atrial 
fibrillation (AF, completed (219)) and 2) measuring MV concentrations and hemostatic 
variables in the acute and convalescent phase of IS/TIA (220). Inclusion criteria were IS/TIA 
within 14 days of recruitment and age above 45/65 years (the age limit was raised during 
inclusion to obtain a representative cohort). Exclusion criteria were known AF or AF on 
admission ECG and inability to operate a handheld ECG device. In total 249 patients were 
recruited. For the analysis of MV and hemostatic variables 38 patients were excluded due to 
patient request, incorrect diagnosis or complete lack of blood samples, resulting in a cohort of 
211 patients. Fifty-three age and sex-matched healthy controls without antithrombotic, anti-
hypertensive, lipid-lowering, corticosteroid or SSRI medication were recruited for 
comparison.  
The exposing factors were MV concentrations in study 3 and thrombin generation variables 
in study 4, as measured in the acute and convalescent phase of IS/TIA. Patients were 
followed until end of 2014 with respect to recurrent ischemic events and all-cause mortality.  
 38 
 
3.2 BLOOD SAMPLING AND PLASMA PREPARATION 
Blood samples were generally taken in the morning, after an over-night fast and after rest for 
at least 10 minutes in semi-reclining position, with no or minimal stasis. (For a minority of 
patients in study 3 and 4, acute phase blood samples were taken just before lunch, due to 
short time between patient recruitment and hospital discharge.) In study 1 and 2 blood 
samples for platelet aggregation tests were drawn in hirudin tubes (Refludan Dynabyte), after 
blood had been collected for routine blood chemistry and metabolic tests (to avoid procedure-
related platelet activation). In study 3 and 4, blood for preparation of PPP was drawn in 
citrate collection tubes (0.129 mM, filled 1:9) and centrifuged immediately at 2000 g for 20 
minutes in room temperature (RT). PPP was then aliquoted and frozen at -80oC until analysis. 
3.3 MEASUREMENT OF PLATELET FUNCTION, MICROVESICLES AND 
THROMBIN GENERATION  
3.3.1 Platelet aggregation tests 
Blood from hirudin test tubes was analyzed by WBA MEA in the MultiplateTM instrument 
(Roche Diagnostics, Basel, Switzerland) within 30-179 minutes of collection, according to 
the manufacturer’s instructions. The method has been described in detail previously (221). In 
brief, 300 µl of whole-blood is diluted 1:1 with 0.9% sodium-chloride solution, and pre-
heated to 37oC in dedicated cuvettes for 3 minutes under stirring. A platelet agonist is 
thereafter added, causing platelets to aggregate on two pairs of silver-coated copper 
electrodes. Platelet aggregation causes an increase in electrical impedance between 
electrodes, which is recorded for 6 minutes. The instrument output is the average area under 
the curve for the two electrode pairs, in arbitrary units (AU). For study 1 and 2 the following 
platelet agonists were used:  
• AA for assessment of the TxA2 pathway (MEA AA). AA was added to a final 
concentration of 0.5 mM.  
• ADP for assessment of the P2Y12 and P2Y1 pathways and effect of clopidogrel 
treatment (MEA ADP). ADP was added to a final concentration of 6.4 µM.  
• TRAP for evaluation of the thrombin receptor PAR-1 pathway. TRAP was added to 
reach 10% of the recommended final concentration, 3.2 µM, to asses sub-maximal 
PAR-1 response (MEA TRAP).  
All reagents and materials were provided by Dynabyte Medical, Munich, Germany. For each 
patient five cuvettes were used: one with AA and two each with ADP respectively TRAP as 
the agonist. In the analysis, the mean of two measurements was used for MEA ADP and 
MEA TRAP. Patients were classified as responders (R) or non-responders (NR) to 
clopidogrel based on a MEA ADP value below respectively above 468 AU, as established by 
receiver-operating characteristics analysis in a previous study and confirmed by consensus 
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(182, 222). (After study 1 and 2, the MEA ADP cutoff was shifted one order of magnitude 
and is now 46 AU.) No cut-off was used for MEA AA or MEA TRAP.  
3.3.2 Measurement of microvesicle concentrations 
MV concentrations in plasma were enumerated by multi-colour flow cytometry. The methods 
for MV isolation and labelling have been described in detail previously (80, 223). In brief, 
one aliquot of PPP (≈ 500µl) was thawed in water-bath at 37oC for 5 minutes and then 
centrifuged in RT for 20 minutes at 2000 g. Thereafter, the supernatant (SN) was centrifuged 
at 13 000 g for 2 minutes. From the resulting MV-rich SN, 20 µl was incubated in the dark 
with 5 µl each of following fluorescent surface markers in suitable combinations (maximum 
four markers per flow cytometer sample):  
• Phalloidin-Alexa660 (Invitrogen, Paisley,UK), binding actin to distinguish cell 
fragments from MV (223). 
• Lactadherin-FITC (Haematologic Technologies, VT, USA) in a concentration of 8 
µg/ml, binding phosphatidylserine (160). 
• Mouse anti-human antibodies to CD41-PC7 (BD, NJ, USA), binding GPIIb of the 
platelet/megakaryocyte receptor GPIIbIIIa. 
• Mouse anti-human antibodies to CD62P-APC (BD, NJ, USA), binding P-selectin.  
• Mouse anti-human antibodies to CD142-PE, (BD, NJ, USA), binding TF.  
After 20 minutes incubation the samples were fixed with low concentration formaldehyde 
(BD Cellfix, Becton Dickinson, CA, USA). For size determination and establishment of the 
MV gate, Megamix beads (0.5, 0.9 and 3.0 µm) were run on separate samples; beads were 
also used for calculation of MV concentrations. Non-specific isotype mouse antibodies were 
as used as negative controls. Samples were analyzed in a Beckman Coulter GalliosTM flow 
cytometer. Gating for MV events was set to size less than 1 µm and negative for phalloidin.  
PMV populations and TF+MV populations not expressing the platelet/megakaryocyte marker 
GPIIb were analyzed according to the hierarchy of figure 5; the subpopulations at lower 
levels are subsets of the population immediately above when connected with a line.  
3.3.3  In vitro thrombin generation by Calibrated Automated Thrombogram 
The in vitro thrombin generation potential was assessed by the Calibrated Automated 
Thrombogram (CAT) assay developed by Hemker et al (224), using the commercial 
instrument from Thrombinoscope (Thrombinoscope BV, Maastricht, Netherlands). In brief, 
thrombin generation in PPP is initiated by the addition of TF, phospholipids and calcium in 
the presence of an excess of a fluorogenic thrombin substrate. As coagulation starts, thrombin 
cleaves the substrate which generates a fluorescent signal. By comparison with a second well 
containing a thrombin calibrator of known concentration, the generated thrombin 
concentration in test plasma as a function of time can be calculated. An example of a CAT 
output curve is shown in figure 6. From this curve, four output variables evaluated in study 4 
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Figure 5: Hierarchy of analyzed MV. All MV populations are a subset of the MV population one level above. P-
sel: P-selectin. GPIIb: marker of the GPIIb moiety of the platelet receptor GPIIbIIIa. MV populations in 
parenthesis were not enumerated.  
 
are obtained as shown in figure 6: lag time (time to start of thrombin generation), peak 
thrombin concentration, time to peak thrombin concentration and endogenous thrombin 
potential (ETP, area under the curve).  
As previously described (220), CAT tests were performed with 80 µl PPP sample per well. 
Reagents were from Thrombinoscope. TF was added to a final concentration of 5 pM and 
phospholipids to a final concentration of 4 µM. Fluorescence was measured every 30 seconds 
for 60 minutes by a Fluoroskan Ascent microwell fluorometer (Fisher Scientific, Vantaa, 
Finland). Tests were performed in triplicate. The four CAT variables were calculated by the 
commercial software of the instrument (Thrombinoscope version 2007).  
3.3.4 In vivo thrombin generation: prothrombin fragment F1+2 
Prothrombin fragment F1+2 is cleaved off when prothrombin is activated to thrombin and 
thus reflects in vivo thrombin generation. F1+2 concentration was measured by a commercial 
ELISA (at the time of testing Dade Behring, now Siemens Healthcare Diagnostics, Marburg, 
Germany). 
3.3.5 Microvesicle-induced thrombin generation potential 
The CAT assay above was modified to assess the thrombin generation capacity of the MV 
pellet, as originally described by Mobarrez et al (67). In brief, one PPP aliquot (≈ 500 µl) was 
thawed in water-bath as above and centrifuged 2000 g for 20 minutes in RT. The MV-rich 
SN was centrifuged 20 800 g for 45 minutes in RT, after which the MV pellet was re-
suspended in phosphate-buffered saline and again centrifuged 20 800 g for 45 minutes. The 
Total MV
PS+MV
PS+PMV (PS
+GPIIb-
MV)
PS-MV
PS-PMV (PS
-GPIIb-
MV)
PS+P-
sel+PMV
PS+TF+
PMV
PS+TF+
GPIIb-MV
PS-P-
sel+PMV
PS-TF+
PMV
PS-TF+
GPIIb-MV
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washed MV pellet was then re-suspended in normal pooled plasma (centrifuged 10 000 g for 
45 minutes in RT). The CAT assay was performed with 80 µl MV-rich plasma, without 
addition of TF or phospholipids. These tests were performed in duplicate for a subset of 
patients in study 4 (96 patients in the acute phase and 98 patients in the convalescent phase). 
 
 
 
 
 
 
 
 
Figure 6: Schematic view of a thrombin concentration curve of the CAT assay, showing lag time (time to start of 
clotting), peak thrombin (peak height), time to peak thrombin and endogenous thrombin potential (ETP).  
 
3.4 METHODS FOR CLINICAL CHARACTERIZATION 
3.4.1 Glucose metabolism and insulin resistance 
Patients in study 1 and 2 were characterized with respect to glucose metabolism and insulin 
resistance. Fasting plasma glucose (fP-glucose) and glycated hemoglobin (HbA1c) were 
measured for all patients. P-glucose was analyzed by glucose oxidase method in Beckman 
Synchron LX 20 (Beckman Coulter Inc, CA, USA). HbA1c, was measured with high 
performance liquid chromatography in a Variant II analyzer (Bio-Rad, Hercules, CA, USA).  
Patients without known diabetes were further characterized by oral glucose tolerance test 
(OGTT) and fasting serum insulin. OGTT was performed according to the guidelines of 
WHO (225), with measurement of p-glucose before respectively 2 hours after ingestion of 75 
g glucose dissolved in water after an overnight fast. According to WHO limits, patients were 
characterized as having:  
• Normal glucose tolerance (NGT): fP-glucose < 6.0 mM and 2h-P-glucose < 7.8 mM. 
• Impaired fasting glucose (IFG): fP-glucose: 6.1-6.9 mM and 2h-P-glucose < 7.8 mM. 
• Impaired glucose tolerance (IGT): fP-glucose < 7.0 mM and 2h-P-glucose 7.9-11.0 
mM. 
• DM : fP-glucose > 7.0 mM or 2h-P-glucose > 11.1 mM. 
Lag time 
Time to peak 
Peak height 
ETP 
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Patients were divided into three groups for the statistical analysis: NGT, IFG/IGT and DM 
(previously known or according to OGTT at the one month control).  
Fasting serum insulin (fS-insulin) was measured in non-diabetic patients by 
ElectroChemiLuminescence Immunoassay (Elecsys Insulin Modular E, Roche Diagnostics, 
Rotkreuz, Switzerland). The degree of insulin resistance (IR) was estimated by the 
Homeostasis Model of Assessment (HOMA-IR), as calculated by the formula: fP-glucose 
(mM) x fS-insulin (mU/l)/22.5 (226). 
3.4.2 Stroke suptype, vessel pathology 
Patients in all four studies were categorized with respect to most likely underlying cause of 
IS/TIA as determined by TOAST classification (227), which specifies the categories: 
• Large-artery atherosclerosis 
• Cardioembolism 
• Small vessel occlusion 
• Other determined cause of stroke 
• Undetermined cause of stroke 
The classification was blinded to all tests of platelet function and thrombin generation, by at 
least two stroke physicians in consensus.  
In study 2, large vessel pathology in carotid arteries was categorized based on carotid 
ultrasound investigations in the acute phase, or, for two patients by CT/MR angiography. 
(Two out of 72 patients were not assessed; one due to symptoms from the vertebro-basilary 
circulation and one where operation of a possible carotid stenosis was considered excluded.) 
The evaluation was performed by the clinical physiology or X-ray departments respectively, 
blinded to all other test results. The degree of atherosclerosis in the internal carotid artery was 
categorized as: 
• 0 p: normal vessel wall 
• 1 p: atherosclerosis/atherosclerotic plaques < 50% of lumen diameter 
• 2 p: carotid stenosis 51-74% 
• 3 p: carotid stenosis 75-99% 
• 4 p: carotid occlusion 
The score reported was the average between the right and left internal carotid arteries, with 
atherosclerosis considered to be present if the score was > 0.5 p, i e atherosclerosis in at least 
one of the internal carotid arteries. 
In study 2, presence of cerebral small vessel disease was assessed using Fazekas scale for 
WMC (228) based on acute CT scans of the brain. Fazekas scale was developed to grade 
periventricular hyperintensities (PVH) and deep white matter hyperintensities (DWMH) on 
MRI and has also been used on CT (229). PVH are graded as absent (0 p), periventricular 
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‘caps’ or pencil-thin lining (1 p), ‘smooth halo’ (2 p) or irregular PVC extending to deep 
white matter (3 p). DWMH are graded as absent (0 p), punctate foci (1 p), beginning 
confluence (2 p) or confluent (3 p). The total Fazekas score is thus 0-6 p. (In the published 
article the total was erroneously 0-9 p, see section 6.1.3.) The correct score was used to 
denote overall WMC as ‘none’ (total 0 p), ‘mild’ (1-2 p), ‘moderate’ (3-4 p) or ‘extensive’ 
(5-6 p); patients were then divided into the categories none-mild WMC versus moderate-
extensive WMC.  
3.4.3 Routine laboratory analyses and evaluation of kidney function 
Routine laboratory analyses were performed at the Clinical Chemistry Laboratory, 
Karolinska University Hospital, Solna, Sweden. Estimated glomerular filtration rate (eGFR) 
was calculated from the plasma creatinine value by the Modification of Diet in Renal Disease 
(MDRD) formula.  
3.5 EVALUATION OF OUTCOME 
For studies 3 and 4, outcome was evaluated until 2014-12-31. Primary outcome was a 
composite of recurrent ischemic events: recurrent IS, AMI or ischemic CVD death. 
Secondary outcomes were fatal/non-fatal recurrent IS or all-cause mortality respectively. The 
following ICD codes were used for recurrent ischemic events:  
• IS: ICD I63.0-6 and I63.8-9. 
• AMI: I21.0-4, I21.9, I22.0-1, I22.8-9, I24.8-9. 
• Ischemic CVD death: I46.0-1, I46.9 or death with any of the above as underlying 
cause. 
Events and date of events were obtained from the Swedish register for in-patient care, the 
Swedish register for cause of death, and where possible confirmed by hospital records. 
Patients were censored after a first outcome event, at the time of death or at the end of follow-
up 2014-12-31. 
3.6 STATISTICAL METHODS 
In studies 1 and 2, R and NR to clopidogrel treatment, as defined by the established cut-off 
above, were compared as independent groups. Group differences of continuous variables 
were analyzed by Student t-test for normally distributed variables and by Mann-Whitney U-
test for non-normally distributed variables. Differences in categorical variables were analyzed 
by χ2 test. In study 1, correlations between MEA values and metabolic variables were 
evaluated by Pearson’s correlation coefficient.  
In study 3 and 4, the methods above were used to compare patients with healthy controls. 
Correlations between independent variables were analyzed by Pearson or Spearman 
correlation coefficient as appropriate. Changes and correlations between acute and 
convalescent phase values were analyzed by paired Student t-test or Wilcoxon signed rank 
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test as appropriate. The statistical analyses of exposing factors versus outcome were 
performed in steps. In a first step, exposing factors were screened by comparing patients with 
and without outcome and analyzing differences by Student t-test or Mann-Whitney U-test as 
appropriate. Variables with p < 0.2 for difference were retained. In a second step, Kaplan-
Meier survival analysis based on median split was performed, and the p-value for difference 
was calculated by log-rank test. Variables with p < 0.1 in the second step were retained for 
Cox regression and calculation of hazard ratios (HR). Multivariate Cox regression was 
performed in a forward, stepwise manner, adjusting for cardiovascular risk factors in order of 
importance in the patient cohort. The number of variables included in the multivariate model 
was limited to have 8-10 patients with events per variable, in order not to overfit the model.  
P-values < 0.05 were considered significant with the exception of variable screening.  
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4 RESULTS 
4.1 STUDY 1 
HPR to clopidogrel treatment is associated with pathological glucose tolerance and 
insulin resistance. 
Out of 66 clopidogrel-treated patients, 14 (21%) had MEA ADP value above the cutoff 468 
AU and were considered NR. In terms of clinical characteristics, NR had higher prevalence 
of known diabetes than R, 36% versus 12%, see table 3. They also had higher frequency of 
previous IS, 43% versus 6%, p= 0.0012. NR had higher leukocyte and platelet count than R, 
but there were no differences in CRP, blood lipids or eGFR. NR also had higher levels of 
MEA AA (840 vs 500 AU, p < 0.0001), suggesting an underlying general platelet hyper-
reactivity. 
Eleven patients in the cohort had known diabetes at inclusion. Based on OGTT at the one 
month control another ten patients were classified as having DM, two had IFG and 15 had 
IGT. Fasting plasma glucose (fP-glucose) was marginally higher in NR than R, but there was 
no significant difference in HbA1c. Pathological glucose tolerance, defined as DM (known or 
according to OGTT) or IFG/IGT, was more common for NR (93%, all but one patient) than 
R (48%), p=0.001, see table 2. Conversely, IFG/IGT appeared to confer a similar risk for NR 
as DM. In non-diabetic patients, HOMA-IR was higher for NR than R, 4.5 versus 2.1, 
p=0.001. Notably, the one NR with NGT had very high HOMA-IR (12.9), suggesting that a 
pre-diabetic/diabetic metabolism is a ‘near pre-requisite’ for HPR to clopidogrel, while NGT 
with normal HOMA-IR appeared to largely preclude HPR.  
 
Metabolic variable R (n =52) NR (n =14) P-value 
DM 2 at incl, n (%)  6 (12%) 5 (36%) 0.045 
fP-glucose, mmol/l, median (IQR) 5.3 (5.0-6.0) 6.0 (5.5-6.7) 0.023 
HbA1c, mmol/mol, median (IQR) 40 (37-44) 42 (34-46) 0.26 
Pathological OGTT/DM, n (%) 25 (48%) 13 (93%) 0.001 
 
Table 2: Variables of glucose metabolism for responders (R) and non-responders (NR) to clopidogrel. Incl: 
inclusion, fP-glucose: fasting plasma glucose, IQR: interquartile range.  
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4.2 STUDY 2 
HPR is associated with WMC, indicating CSVD, but not carotid artery sclerosis.  
After completed recruitment, there were 72 patients on clopidogrel treatment at the one 
month control (61 of which were analyzed in study 1, see section 3.1.1 for details). Sixteen 
patients were NR (22%). The above differences between NR and R with regard to clinical 
and laboratory characteristics and variables of glucose metabolism were confirmed in this 
somewhat larger patient cohort. The concept of a general platelet hyper-reactivity for NR was 
further supported by significantly higher MEA TRAP for NR compared to R, both at 
inclusion and the one month control (310 versus 160 AU and 245 versus 160 AU 
respectively, p < 0.01 for both). 
Concerning IS subtype, there was no statistical difference in the distribution of TOAST 
categories between NR and R. To assess the importance of existing vessel changes, patients 
were evaluated with respect to carotid atherosclerosis, reflecting large artery atherosclerosis 
disease, and WMC on CT scans of the brain, indicating presence of CSVD. Overall, 51% of 
patients had carotid atherosclerosis. Contrary to our original hypothesis, there was no 
difference in the prevalence or severity of carotid atherosclerosis between NR and R, see 
figure 7. Neither was there any difference between NR and R in the prevalence of other 
atherosclerotic manifestations such as history of ischemic heart disease or peripheral artery 
disease. Moderate-extensive WMC were found in 23 patients (32%) and was significantly 
more common in NR (56%) than R (25%), OR 3.9 (CI 1.2-12, p=0.03), see figure 7. A 
subgroup analysis based on the categories ‘no vessel changes’ (20 patients), ‘isolated carotid 
atherosclerosis’ (28 patients), ‘isolated WMC’ (14 patients) and ‘both carotid atherosclerosis 
and WMC’ (8 patients), suggested that only WMC was associated with clopidogrel non-
response; the prevalence of NR in patients with isolated carotid atherosclerosis was similar to 
that in patients without vessel changes.  
 
 
Figure 7: Prevalence of vessel changes in non-responders (NR) and responders (R) to clopidogrel; carotid 
atherosclerosis (55 R, 15 NR) and white matter changes (56 R, 15 NR). *) p < 0.05. 
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Based on the above result, patients were characterized in more detail, in particular with 
respect to hypertension. While there was no significant difference in the prevalence of 
hypertension at inclusion, all NR had hypertension (diagnosed or treated) at the one month 
control, versus 64% of R. NR also had more intensive anti-hypertensive treatment than R, but 
still had higher systolic blood pressure at the one month control, median 145 versus 135 mm 
Hg, p=0.02. Also the pulse pressure was higher for NR than R, which may suggest increased 
arterial vessel stiffness. NR thus had both higher prevalence of pre-diabetic metabolic 
changes and more advanced hypertension than R.  
The study cohort was not large enough to perform a multivariate Cox regression analysis of 
which clinical variables were independently associated with HPR as there were only 16 
patients with HPR. A multivariate linear regression model was performed to investigate 
which variables were predictive of the MEA ADP value. The traditional CVD risk factors 
age, sex, smoking, hypertension and diabetes together gave an R2 value of 0.13 (adjusted 
0.064); thus explaining only 13% of the variance in MEA ADP. In contrast a model with age, 
pathological glucose tolerance/DM, BMI, platelet count and leukocyte count resulted in R2 of 
0.47 (adjusted 0.43), thus explaining almost half of the variance in MEA ADP. In this model, 
hypertension and WMC were not found to give a further independent contribution to MEA 
ADP. These results were presented as poster at the International Society on Thrombosis and 
Haemostasis conference in Toronto 2015. 
4.3 STUDY 3 
PMV, TF+MV and their subpopulations are enhanced in both the acute and 
convalescent phase of IS/TIA. The associations with outcome differ between MV 
populations and depend on the time of measurement.  
Blood samples for MV enumeration were available for 199 out of 211 patients in the acute 
phase and 189 patients in the convalescent phase. The follow-up time for patients with MV 
data was 1100 patient years. The primary outcome recurrent ischemic event occurred in 54 
patients in the cohort. Secondary outcome recurrent ischemic stroke occurred in 43 patients, 
and 31 patients died.  
4.3.1 Cross-sectional evaluation of circulating MV in the acute and 
convalescent phase compared to matched controls 
Compared to healthy controls, patients had higher levels of all enumerated MV populations in 
the acute phase (p < 0.0001 for all), see figure 8. Differences were particularly pronounced 
for PMV expressing the activation markers P-selectin and TF, both for populations positive 
and negative for PS, which were median 7-77 times higher in patients than controls. MV 
levels generally remained high in the convalescent phase. MV populations had different 
temporal profiles between the acute and convalescent phase. MV expressing PS and/or TF 
decreased, while PS-MV, PS-PMV and PS-PMV expressing P-selectin increased between the 
acute and convalescent phase. PS+MV and PS-MV populations with otherwise identical 
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surface markers were not correlated, neither in healthy controls nor in patients at either 
measurement time.   
 
Figure 8: Concentrations of total MV (A), PS+MV populations (B) and PS-MV populations (C). *** p<0.0001, 
NS: non-significant. 
4.3.2 Associations between MV populations and outcome 
The screening of MV populations versus outcome gave negative results for several types of 
MV expected to be pro-thrombotic. Thus, comparing patients with and without primary 
outcome there were no significant differences in the levels of PS+TF+PMV or PS+TF+MV 
lacking the platelet marker GPIIb (TF+MV of non-platelet origin) neither in the acute nor 
convalescent phase. Furthermore, levels of PS+PMV expressing P-selectin, generally viewed 
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upon as reflecting platelet activation, were similar in patients with and with primary outcome. 
Notably, the only MV population with a positive association to primary outcome in variable 
screening lacked pro-coagulant PS. Thus PS-TF+PMV above median in the acute phase gave 
an unadjusted HR 1.72 for primary outcome, see figure 9B. Adjustment for cardiovascular 
risk factors diabetes, eGFR, age and male sex resulted in a significant HR 1.86 (CI 1.04-3.31, 
p=0.036) with p=0.001 for the model. In contrast, PS+PMV above median in the acute phase 
conferred a reduced risk for primary outcome with crude HR 0.59, see figure 9A. This 
association was not independent of cardiovascular risk factors. Interestingly, there was 
moderate negative correlation between PS-TF+PMV and PS+PMV measured in the acute 
phase, r=-0.35, p < 0.0001.  
 
Figure 9: Univariate Kaplan-Meier survival curves for PS+PMV and PS+TF-PMV in the acute phase versus 
primary outcome. Red curves: concentrations above median, black curves: concentrations at and below median.  
In the convalescent phase, variable screening showed PS-P-sel+PMV to be inversely 
associated with primary outcome, figure 10A, and PS+TF+MV of ‘non-platelet origin’ to be 
inversely associated with the secondary outcome recurrent IS, figure 10B. These MV 
populations thus appeared to confer reduced risks, but associations were not significant after 
adjustment for cardiovascular risk factors.  
None of the enumerated MV populations at either measurement point were associated with 
the secondary outcome all-cause mortality.  
 
Figure 10: Univariate Kaplan-Meier survival curves for convalescent concentrations of PS-P-sel+PMV versus 
primary outcome and PS+TF-GPIIb-MV versus secondary outcome recurrent IS. Red curves: concentrations 
above median, black curves: concentrations at and below median.  
 50 
4.4 STUDY 4 
High peak thrombin and ETP measured in the acute phase of IS/TIA is associated with 
reduced risk of recurrent ischemic events. High MV-induced thrombin generation in 
the acute phase is associated with increased risk of recurrent IS.  
The relationships between thrombin generation variables and outcome were evaluated in the 
same patient cohort as above. Excluding patients with anticoagulant treatment there were 190 
patients in the cohort; of these 180 patients in the acute phase and 181 patients in the 
convalescent phase had data on thrombin generation. The follow-up period with respect to 
primary outcome was 986 patient years. In this cohort, primary outcome occurred in 46 
patients and the secondary outcome recurrent IS in 36 patients; 25 patients died.  
4.4.1 Cross-sectional evaluation of thrombin generation variables in the 
acute and convalescent phase as compared to healthy controls.  
Baseline CAT data were reported previously, showing higher peak thrombin in patients in the 
acute and convalescent phase, and higher ETP in the acute phase as compared to healthy 
controls (220). Median F1+2 was lower in patients than in healthy controls, both in the acute 
and convalescent phase (170 and 207 versus 243 pmol/l, p < 0.001 and p < 0.05 respectively). 
In the subset of patients tested for MV-induced thrombin generation, MV peak thrombin 
(MV-PT) and MV thrombin generation potential (MV-TGP) were higher in patients than 
healthy controls, both in the acute and convalescent phase (MV-PT 117 and 115 vs 87 nM, p 
< 0.001 for both). MV lag time and MV time to peak were also marginally shorter.  
4.4.2 Association between thrombin generation variables and outcome 
Screening of CAT variables with respect to outcome unexpectedly showed lower acute phase 
values of peak thrombin and ETP in patients with events as compared to those without. The 
Kaplan-Meier survival curves based on median split confirmed a reduced risk in patients with 
peak thrombin or ETP above median both with respect primary outcome, see figure 11A) and 
B), and secondary outcome recurrent IS (data not shown). Hazard ratios for both outcomes 
remained significant after adjustment for cardiovascular risk factors, HR 0.40-0.53, p <0.05 
for all associations.  
Variable screening showed no significant association between F1+2 and outcome.  
In the subset of patients tested for MV-induced thrombin generation potential, MV-PT and 
MV-TFP measured in the acute phase were positively associated with the secondary outcome 
recurrent IS in an unadjusted analysis. The Kaplan-Meier curve for MV-PT is shown in 
figure 11C). The number of events in this group was too small to allow adjustment for 
cardiovascular risk factors.  
There were no significant associations between thrombin generation variables and all-cause 
mortality.  
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Figure 11: Univariate Kaplan-Meier survival curves based on median split. Red curves: values above median; 
black curves: values at median and below. A) ETP measured in the acute phase versus primary outcome B) peak 
thrombin measured in the acute phase versus primary outcome and C) MV-PT (peak thrombin) in the acute 
phase versus secondary outcome recurrent IS (a subset of patients). 
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5 DISCUSSION 
5.1 STUDY 1 AND 2 
In study 1 and 2, several clinical variables were found to be associated with HPR under 
clopidogrel treatment by univariate analysis 1) pathological OGTT/DM, 2) insulin resistance, 
3) hypertension and 4) WMC indicative of CSVD. In addition, patients with NR had 
significantly higher platelet aggregation response to AA and submaximal TRAP stimulation 
than R, as well as higher platelet and leukocyte counts. Together these results suggest that 
HPR to clopidogrel to an important extent reflects a general platelet hyperreactivity, as has 
been proposed by others for patients with CAD (182, 186).  
5.1.1 High on-treatment platelet reactivity and impaired glucose tolerance 
At the time of study 1, the elevated risk of HPR in patients with DM was well-known in CAD 
patients (182, 230), but the association between HPR and IFG/IGT had not been investigated 
to our knowledge. The importance of DM for clopidogrel response for IS patients was 
confirmed in a study by Meves et al in 2014. They investigated HPR by MEA in 159 
clopidogrel-treated patients shortly after acute IS (231). The prevalence of HPR was 44% 
after on average two days of clopidogrel treatment. (In a subset of HPR patients retested after 
one week only 43% retained HPR status, suggesting a prevalence under maintenance 
treatment similar to the one we found.) In a multivariate analysis only DM and platelet count 
were independently associated with HPR; glucose tolerance was not investigated. 
In 2015, Ueno et al evaluated OGTT, insulin resistance and platelet aggregation measured by 
LTA in 65 non-diabetic CAD patients on dual antiplatelet treatment with aspirin and 
clopidogrel, tested in the stable phase after PCI (232). IGT was found in 30 patients and NGT 
in 35. Patients with IGT had clearly higher rates of HPR than those with NGT, and IGT was 
the only independent predictor of HPR in a multivariate analysis (OR 7.5), supporting our 
results. More than 55% of patients with IGT had HPR, while HPR was found in less than 
15% of patients with NGT. In comparison we found HPR in only 2/32 patients (6%) with 
NGT, one of whom had insulin resistance. Together the two studies suggest the possibility to 
use OGTT as a tool to risk stratify non-diabetic patients with respect to HPR, which merits 
further investigation.  
5.1.2 High on-treatment platelet reactivity and insulin resistance 
We found HOMA-IR to be about twice as high for NR as R to clopidogrel. Insulin resistance 
was also evaluated in the above study by Ueno et al; 13/65 patients (20%) had insulin 
resistance, defined as HOMA-IR > 2.5; eight of these also had IGT (232). Patients with 
insulin resistance had higher platelet aggregation than those without, but insulin resistance 
was not an independent predictor of HPR in the multivariate analysis. However, the platelet 
aggregation response during OGTT, measured at baseline, and at 1 h and 2 h, deviated for 
patients with IR as compared to those without, in that it did not decrease over time. Together 
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our results and the Ueno study suggest an association between insulin resistance and HPR to 
clopidogrel. Larger studies are needed to determine if insulin resistance is associated to HPR 
independently of IGT.  
With respect to mechanisms that could be involved in the association between insulin 
resistance and HPR, the enzyme/chaperone protein PDI is highly interesting. PDI was 
released from activated endothelium and platelets in the laser-induced thrombosis model and 
was found necessary for thrombus formation (105). PDI inactivates insulin in vitro by 
reducing disulfide bonds resulting in separation of the insulin A and B chains (233). PDI is 
expressed on the platelet surface of platelets even before they are activated (234). Circulating 
PMV from healthy controls expressed PDI with enzymatic capacity to reduce insulin, and 
PDI on PMV substantially contributed to platelet aggregation (233). Further, these PDI-
positive PMV were found elevated in patients with DM type 2. The role of PDI as a mediator 
of both platelet hyper-reactivity/HPR and insulin resistance merits further investigation, see 
section 1.3.4.1. Of note, targeting PDI has recently been proposed as a novel antiplatelet 
treatment (235).  
5.1.3  High on-treatment platelet reactivity and hypertension 
In study 2 several findings supported an association between HPR and hypertension. At the 
one month control, patients with HPR had higher prevalence of hypertension, higher systolic 
blood pressure, higher pulse pressure and more intensive antihypertensive treatment than 
those with normal clopidogrel response. Hypertension has been proposed to increase platelet 
reactivity (see section 1.3.5.4) but an association to HPR was not established at the time of 
study 2. Supporting our finding, Kukula et al recently found hypertension to be a associated 
with HPR as measured by MEA in CAD patients (236). Further, in a study on ACS patients 
Verdoia et al found that hypertension influenced the MEA ADP response under ticagrelor 
treatment (237). Whether there is an independent association remains to be established. 
5.1.4 High on-treatement platelet reactivity and ischemic stroke subtype, 
white matter changes and carotid atherosclerosis 
Concerning IS subtype, there was no difference in the distributions of TOAST classifications 
between patients with and without HPR. The study was small and had only 16 patients with 
HPR, likely making it underpowered in this respect. Furthermore, TOAST is a relatively 
blunt classification tool, with overrepresentation in the ‘undetermined’ category, which may 
have contributed to the lack of difference. We also investigated associations between HPR 
and existing vessel changes. Contrary to our original hypothesis there was no association 
between HPR and carotid atherosclerosis or other manifestations of large artery 
atherosclerosis. As most patients had minor IS or TIA, the overall atherosclerosis burden in 
this cohort may have been too limited to reveal an association and there were also 
methodological limitations, see section 6.1.3. However, it is notable that patients with carotid 
atherosclerosis had a similar HPR prevalence to those without any discernable vessel 
changes.  
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In contrast to the result for atherosclerosis, HPR was associated with moderate to extensive 
WMC, indicative of CSVD. One possible explanation could be a confounding effect of 
hypertension and impaired glucose tolerance; these factors may contribute to both increased 
platelet reactivity and WMC without a causal relationship between the two. However, 
considering the recent finding that cardiovascular risk factors explain only a small part of the 
variance in WMC (34), this explanation is not entirely convincing. In a small study by 
Oberheiden et al, patients with mild, moderate or extensive WMC according Fazekas scale 
had higher platelet expression of CD40L and P-selectin in flow cytometry than to healthy 
controls (46). They also had higher number of platelet-monocyte aggregates and higher 
monocyte TF expression. The authors proposed that platelet activation may be a pathological 
factor in CSVD. Other studies for patients with IS have often found higher platelet activation 
in large vessel disease as compares to lacunar IS, in particular in the acute phase (45).  
One factor that may differ between large vessel atherosclerosis and CSVD is shear-induced 
platelet activation. As the carotid arteries are among the larger in the body, they have low 
shear under normal conditions and significant stenosis is required for shear-induced platelet 
activation in these vessels. In addition, carotid atherosclerosis/stenosis occurs over a limited 
distance, typically a few centimeters, representing on a limited part of the platelet ‘time-of-
flight’ in the circulation. Holmes et al showed that shear rates of about 10 000 s-1, 
corresponding to more than 80% stenosis in coronary vessels, were required to achieve shear-
induced platelet activation ex vivo; the time of shear exposure and geometry of stenosis were 
also important (238). CSVD on the other hand, affects the small arteries and arterioles, where 
shear is high also under healthy conditions and microstenoses can potentially cause extreme 
shear values. Further, CSVD involves diffuse changes throughout the cerebral vascular tree, 
where platelets can be exposed to shear-induced activation for longer times. Similar 
arguments could be applied also to platelet interactions with the dysfunctional endothelium in 
CSVD, where there is likely more time and larger surface area for interactions than for large 
vessel lesions. Thus we propose that shear-induced platelet aggregation and/or cerebral 
endothelial dysfunction in CSVD could be contributing factors to the association between 
HPR and WMC. As study 2 was small, the association between HPR and CSVD should be 
confirmed in larger studies using MRI, which has the added advantage that it can quantify the 
different manifestations of CSVD and establish their individual associations with HPR.  
5.1.5 Multivariate analysis 
An important question with respect to the above clinical variables is which of them are 
independently associated with HPR. The total number of NR was not sufficient to perform a 
multivariate Cox regression, and instead a multivariate linear regression model was used to 
investigate which variables predicted MEA ADP. In this model pathological glucose 
tolerance/DM, age, BMI, platelet count and leukocyte count were predictors of MEA ADP. 
Hypertension, insulin resistance and CSVD did not give a further independent contribution, 
likely partly due to covariance with the other variables. The variables of the model explained 
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almost half of the MEA ADP variance. Factors explaining the remaining half could include 
variations in clopidogrel absorption and metabolism, drug interactions and other genetic 
aspects of platelet function.  
5.1.6 Conclusions 
In summary, HPR appears to be at least as common in patients with IS/TIA as in patients 
with ACS (239), despite the fact that the former are not exposed to thrombogenic stents. The 
recent meta-analysis by Fiolaki et al suggests that the clinical consequences of HPR in terms 
of risk for recurrence are also similar for IS/TIA as for ACS (207). While it is clear that HPR 
is a risk marker, it is less clear how it should be handled clinically. For patients with CAD the 
present recommendation is that platelet function testing may be considered in selected, high-
risk patients on dual antiplatelet therapy with aspirin and clopidogrel (240, 241). However, 
for patients with IS/TIA, clopidogrel is given as monotherapy and often indefinitely. 
Screening of IS/TIA patients with high risk of HPR could therefore be warranted. Studies 1 
and 2 identified pre-diabetic metabolic changes, advanced hypertension and presence of 
WMC as important factors for HPR. The importance of these factors should be confirmed in 
larger cohorts, but together they provide an indication of which patient groups may benefit 
the most from targeted platelet function tests.  
With respect to interventions, our results suggest that HPR may respond to life-style changes 
and more aggressive risk factor management. As the risk of HPR is increased already in the 
pre-diabetic phase, life-style changes such as exercise, weight-loss and improved diet could 
conceivably reduce the prevalence of HPR in pre-diabetic patients. It would also be highly 
interesting to investigate whether medication that improves plasma glucose and insulin levels 
could reduce HPR in non-diabetic patients. In this respect metformin is of particular interest, 
as it reduces plasma glucose and improves insulin sensitivity without causing hypoglycemia.  
It would intuitively seem appropriate to change clopidogrel to other antiplatelet treatment in 
IS/TIA patients with HPR. Lending some support to this concept, the PROFESS subgroup 
analysis suggested that aspirin with dipyridamole may be superior to clopidogrel for patients 
with diabetes, small vessel disease and patients with previous IS/TIA (13). However, if the 
association between HPR and CSVD is confirmed, IS/TIA patients with HPR may also be at 
increased risk of bleeding (5), which makes the selection of antiplatelet treatment more 
complicated. Since one effect of HPR is insufficient cAMP levels in platelets, addition of 
dipyridamole or cilostazol to clopidogrel would be interesting, in particular as these 
substances are not expected to increase bleeding risk substantially.  
5.2 STUDY 3 
Study 3 investigated PMV and TF+MV subpopulations and their association with prognosis, 
and generated a number of results. Several were unexpected and/or contradicted our original 
hypotheses. While the majority of detected MV expressed PS, a PS-negative population was 
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the only one with a positive association with prognosis. PS+MV populations displayed no 
association or unexpected protective effects.  
As expected PMV populations expressing activation markers P-selectin or TF showed more 
pronounced elevations relative to healthy controls than overall PMV levels but the individual 
associations with recurrent events and relative changes between the acute and convalescent 
phase differed between PMV populations.  
5.2.1 Platelet microvesicles and P-selectin-positive platelet microvesicles 
Overall PS-PMV and PS-P-sel+PMV showed stronger elevations relative to healthy controls 
than their PS+ counterparts. Also the proportions of PMV positive for P-selectin were higher 
for PS-PMV than for PS+PMV, 68% versus 46% in the acute phase and 68% and 33% in the 
convalescent phase. These results may partly be due to ‘diluting’ effect of PS-positive, 
megakaryocyte-derived MV which would be counted as PS+PMV (79). In support of this 
hypothesis, the median concentrations of PS+PMV lacking P-selectin were similar for 
patients in the acute and convalescent phase and for healthy controls (8 570, 8 563 and 8 338 
/µl respectively). These MV could thus comprise constitutively released megakaryocyte MV; 
however, this hypothesis would have to be confirmed by evaluating megakaryocyte-specific 
MV markers (79). In comparison with PS+PMV, P-selectin positive PMV would appear to be 
more appropriate markers of platelet activation, as suggested by others (80, 83). However, 
there were notable differences between PS+P-sel+PMV and PS-P-sel+PMV, both in dynamic 
behavior and association with recurrence. PS+P-sel+PMV decreased between the acute and 
convalescent phase, as would be expected after a thrombotic event. In contrast PS-P-sel+PMV 
increased between the acute and convalescent event. A discussion of possible explanations 
for this result by necessity becomes speculative, as the PS-PMV generation mechanisms and 
binding/clearance mechanisms are presently unknown. Shear-induced platelet activation has 
been shown to result in PMV release ex vivo (238); it was not specified to what extent these 
expressed PS. Considering that shear-induced platelet activation may be reversible and does 
not require platelet PS-exposure (119), it is tempting to speculate that shear-induced platelet 
activation could generate PS-PMV. Another interesting hypothesis is that PS+PMV and PS-
PMV may, in the setting of thrombosis, be released from PS+ and PS- platelet subpopulations 
respectively. Munnix et al found aggregating plaletets to be PS- and while procoagulant 
platelets were PS+ (113). While in vitro experiments indicate that PS+ procoagulant platelet 
are particularly prone to MV release, some MV appeared to be released also from 
aggregating platelets (115). It would be interesting to investigate if PS+P-sel+PMV correlate 
with the propensity to form PS+ platelets in vitro. As to binding and/or clearance, platelets 
adhere to cerebral ischemic microvesseles in IS (198) and similar effects may occur with 
PMV, which would decrease the concentration of circulating PMV. In this respect it would be 
interesting to subtype PS+P-sel+PMV and PS-P-sel+PMV further with respect to adhesion 
molecules that mediate interactions with the endothelium. Similarly, IS leads to leukocyte 
activation, in particular monocytes and neutrophils, and hypothetically leukocyte binding of 
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PS+P-sel+PMV and PS-P-sel+PMV could differ, which could influence their circulating 
concentrations. 
Concerning associations with prognosis, PS+PMV overall in the acute phase and PS-P-
sel+PMV in the convalescent phase appeared to be inversely associated with prognosis, 
although the associations were not significant after adjusting for cardiovascular risk factors. 
Other PMV populations did not have any association with outcome. The reasons for these 
unexpected results are unknown. It is possible that platelets in high-risk patients are 
chronically activated and ‘exhausted’, leading to a suppressed platelet response in connection 
with a thrombotic event. It has also been reported that PMV can have an anticoagulant effect 
which may explain a protective effect (74). Also the timing for PMV measurement should be 
considered: PMV responses in the acute and early convalescent phase of IS/TIA may not be 
associated with long-term risk. It cannot be excluded that measurement in a more stable phase 
(3-6 months) would reveal other associations.  
5.2.2 Tissue factor positive microvesicles and platelet microvesicles 
Several findings are notable for TF+MV populations after IS/TIA. Firstly, TF+PMV were 
drastically elevated levels in patients as compared to healthy controls: median PS+TF+PMV 
was 77 times higher for patients in the acute phase and 49 times higher in the convalescent 
phase. For PS-TF+PMV the corresponding figures were 15 and 11 times. Further, the absolute 
levels were substantially higher than those previously found by our group for patients with 
ACS by the same method (80). While results are not directly comparable due to minor 
differences in flow cytometry settings, the difference was about one order of magnitude, 
while concentrations for healthy controls were comparable. Further, for patients a clear 
majority of TF+MV expressed the platelet marker GPIIb, almost 90% both in the acute an 
convalescent phase, while for healthy controls the corresponding figure was only about 30%. 
Finally, only PS-TF+PMV measured in the acute phase were positively associated with 
recurrent events; PS+TF+PMV were neutral and PS+TF+MV of non-platelet origin measured 
in the convalescent phase appeared protective.  
As discussed in section 1.3.3.3, TF+MV, their source and clinical importance are 
controversial. Most studies have identified monocytes as the most likely source of TF+MV. 
TF+PMV have been detected in several studies (80, 242), but after del Conde et al showed 
that activated platelet could take up monocyte-derived TF+MV (96), the original TF source 
has still largely been assumed to be monocytes. We found concentrations of TF+PMV to be 
much higher than concentrations of TF+MV of non-platelet origin (about one order of 
magnitude), putting this concept into question. There are reports both demonstrating and 
disproving the presence of TF in resting and activated platelets, recently excellently 
summarized in (101). Our results suggest that platelets are strongly involved in the generation 
of TF+MV after IS/TIA, however it cannot be excluded that TF+PMV are hybrid MV 
generated by interactions with leukocytes. Interestingly, Leon et al found platelet expression 
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of TF, where TF was inactive in its native form, but could be activated by platelet-neutrophil 
interactions in vitro in an ADP-dependent manner (242).  
The difference in TF+PMV concentrations of patients with IS/TIA as compared to patients 
with ACS is notable, and suggests differences in TF+PMV formation in cerebral as opposed 
to coronary vessels. It is possible that increased permeability of the blood-brain barrier is 
involved, as the brain is particularly rich in TF which may leak into the circulation and be 
taken up by platelets. Such effects have been demonstrated in traumatic ICH (243). However, 
cerebral TF is would be expected to be active, of which we have no evidence. In fact, the TF-
positive population with the highest concentration, PS+TF+PMV, was not associated with 
prognosis, which suggests that TF is inactive on these PMV. Also, none of the TF+MV 
subpopulations in patients correlated with any of the thrombin generation variables in study 
4. It would be interesting to investigate if PS+TF+PMV and PS-TF+PMV differ in their 
expression of PSGL-1, which could influence their incorporation into thrombi.  
5.2.3 Conclusions 
Overall PMV and TF+MV levels are not associated with recurrence in patients with minor 
IS/TIA, but specific populations measured in the acute and convalescent phase display 
associations with either increased risk (PS-TF+MV in the acute phase) or decreased risk 
(PS+PMV in the acute phase, PS-P-sel+PMV and PS+TF+GPIIb-MV in the convalescent 
phase). A more detailed subtyping to these MV populations may provide insights into platelet 
activation mechanisms and possibly cell interactions underlying an increased respectively 
decreased risk of recurrent events in patients with IS/TIA. The study also emphasizes the 
importance of the timing of MV measurement in relation to symptoms, as both MV levels 
and their association with outcome change between the acute phase and one month after 
symptoms. 
5.3 STUDY 4 
As in study 3, the results in study 4 were unexpected and partly contradicted the original 
hypotheses. Despite the fact that acute phase values of both ETP and peak thrombin were 
elevated in patients as compared to healthy controls, high levels of ETP and peak thrombin 
were associated with a reduced risk of recurrent ischemic events. In contrast, high MV-
induced peak thrombin and MV thrombin generation potential in the acute phase increased 
the risk of recurrent IS in the subset of patients tested. F1+2 was lower in patients than 
healthy controls and tended to be lower in patients with recurrent events than those without 
but was not significantly associated with outcome. 
One previous population-based study on IS and one small study on ACS patients have found 
low ETP to be positively associated with outcome (244, 245). In both studies it was proposed 
that high risk patients may have elevated thrombin generation in vivo which would result in 
decreased in vitro thrombin generation, explaining the associations. We measured F1+2 as 
marker of in vivo thrombin generation and found that it was lower in patients than healthy 
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controls and also tended to be lower in patients with primary outcome than those without (at 
least in the convalescent phase). In addition, there was no indication of larger infarction in 
patients with recurrent events as stroke severity was the same in patients with and without 
primary outcome, both in the acute phase and at the one month control. It is thus difficult to 
reconcile our results with a pure consumption effect. The modified MV-induced CAT assay 
uses normal pooled plasma and is not dependent on patient concentrations of 
coagulation/anticoagulation factors. The fact that this assay had a positive association with 
the outcome recurrent IS suggests that coagulation/anticoagulation may be ‘rebalanced’ after 
IS/TIA in high risk patients. Possibly MV populations may be involved in this ‘rebalancing’ 
but we found no clear correlations between the MV-populations measured in study 3 and 
peak thrombin or ETP. With respect to ‘rebalancing’ of coagulation/anticoagulation it would 
be interesting to evaluate TFPI, which has often been found increased in CVD (246). 
The associations to outcome differed somewhat between ETP and peak thrombin. A 
somewhat stronger association was found for ETP, in particular with respect to recurrent IS. 
Also, the Kaplan-Meier curves suggested that high ETP was particularly protective against 
early recurrences while the for peak thrombin the curves separated later (1-2 years). The 
study was not large enough to test these findings for statistical significance. It would be 
interesting to test the predictive potential of the combination of low ETP and high MV-TP in 
a larger study.  
5.4 OVERALL DISCUSSION OF STUDY 3 AND 4 
Together study 3 and 4 suggest that in patients with high risk of recurrent ischemic event, the 
response of the hemostatic system to a thrombotic event is disturbed in the acute phase. This 
disturbance is characterized by increased PS-TF+PMV, possibly decreases in other PMV 
subpopulations, reduced levels of ETP and peak thrombin and, for recurrent IS, increased 
levels of MV-induced thrombin generation and MV-induced peak thrombin. Some of these 
variables appear to have a particular importance for early recurrences when the relative risk 
per time interval is highest, notably ETP. If the underlying mechanisms could be uncovered, 
this may lead to the discovery of treatment targets to reduce early recurrence.  
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6 METHODOLOGICAL LIMITATIONS 
6.1 STUDY 1 AND 2 
6.1.1 Definition of high on-treatment platelet reactivity 
We used the MEA ADP cut-off for HPR agreed by cardiological consensus (182). This value 
comes from a medium-sized cohort (1608 patients) going through planned PCI due to ACS or 
stable angina after a loading dose of 600 mg of clopidogrel (222). The cut-off was established 
by receiver-operating characteristics analysis of AMI in the first month comprising 10 cases, 
most of which occurred in the first week after PCI. The conditions of our study differ from 
the above in almost all aspects. As was noted in the consensus document, the appropriate cut-
off value may be different in patient cohorts with CVD other than ACS/PCI (182). Ideally a 
larger study should be performed to establish the optimal HPR cut-off for IS/TIA patients.  
6.1.2 Insulin resistance 
Insulin resistance was assessed by HOMA-IR, which is a surrogate index; definite diagnosis 
of insulin resistance requires testing with hyperinsulinemic, euglycemic clamp. The 
correlation between the two methods is good for patients with a limited loss of β-cell (226). 
As the latter condition was likely met for the majority of patients tested, the error is likely 
limited, but hyperinsulinemic, euglycemic clamp may be required to establish an independent 
association between HPR and insulin resistance.  
6.1.3 Diagnosis of vessel changes 
The degree of carotid atherosclerosis was evaluated based on clinical ultrasound 
investigations aimed at identifying carotid stenosis with indication for surgery. A research-
based protocol including measurement of carotid-intima thickness would have been more 
appropriate. We can thus not exclude an association between large vessel and HPR.  
The degree of WMC was evaluated on CT scans of the brain, while Fazekas scale was 
developed for MRI. Wattjes et al show good correlation of Fazekas scale on modern CT 
instruments compared to MRI (229), but we cannot exclude some misclassification where 
lacunes may have been interpreted as WMC. Both lacunes and WMC are manifestations of 
CSVD and they are correlated in studies, but differences in detailed pathophysiology cannot 
be excluded. Ideally a larger study should be performed relating HPR to CSVD 
manifestations on MRI. Also, by a misunderstanding of the Fazekas scale, DWMC were 
counted twice, both for characteristic appearance and number of DWMC. This resulted in a 
total Fazekas score of 0-9 points instead of 0-6 points. As the main result was obtained after 
dichotomizing the ordinal scale, we do not think this error influences our conclusions.  
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6.1.4 Statistical methods 
In study 1, correlations between MEA ADP and variables of glucose metabolism were 
calculated by Pearson’s correlation coefficient. As the variables were non-normally 
distributed, Spearman’s correlation coefficient should have been used.  
6.2 STUDY 3 
PPP was prepared by a single centrifugation step, while presently double centrifugation to 
obtain platelet-free plasma is recommended to avoid in vitro generation of PMV or platelet 
fragments being counted as PMV (247). MV enumeration was performed before the 
guidelines were established. As we have used phalloidin to avoid counting platelet fragments 
(223), and data indicated low number of these events, the error introduced by single step 
centrifugation should be minimal.  
6.3 STUDY 4 
The modified CAT assay for determining MV-induced thrombin generation in normal pooled 
plasma was performed without addition of corn trypsin inhibitor and thus includes the contact 
pathway contribution to thrombin generation. Notably, it was recently reported that no 
measurement of MV-induced thrombin generation could not be obtained when adding corn 
trypsin inhibitor to the assay (248).  
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7 CONCLUSIONS 
• High on-treatment platelet reactivity (HPR) under clopidogrel treatment in the stable 
phase after ischemic stroke (IS) or TIA was common and observed in approximately 
one of five patients. 
• Patients with HPR to clopidogrel tended to have stronger platelet responses to 
arachidonic acid and thrombin receptor activating peptide compared to those who 
responded normally to clopidogrel. 
• HPR to clopidogrel was associated with disturbed glucose metabolism, insulin 
resistance, advanced hypertension and radiological signs of cerebral small vessel 
disease (CSVD). 
• HPR to clopidogrel was not associated with carotid atherosclerosis or other 
manifestations of large artery atherosclerosis.  
• Platelet microvesicles (PMV) expressing activation markers P-selectin or tissue factor 
(TF) were strongly elevated in the acute phase of IS/TIA and remained elevated in the 
convalescent phase one month after symptoms.  
• Several PMV subpopulations expected to be prothrombotic were not associated with 
outcome, neither in the acute nor the convalescent phase. 
• PMV expressing TF but lacking phosphatidylserine measured in the acute phase were 
positively and independently associated with poor outcome. 
• Several MV subpopulations appeared to be inversely associated with poor outcome, 
suggesting a protective effect. 
• Chronic activation with ‘platelet exhaustion’ in high risk patients may explain the 
seemingly protective effect of certain PMV populations. 
• Further research is required to determine if different PMV populations reflect 
different types of platelet activation.  
• In vitro thrombin generation in plasma, assessed as endogenous thrombin potential 
and peak thrombin measured in the acute phase, were associated with reduced risks of 
recurrent ischemic events.  
• In addition, thrombin generation in vivo was lower in patients than healthy controls, 
and not associated with outcome.  
• MV-induced thrombin generation and peak thrombin measured in the acute phase, 
were associated with an increased risk of recurrent ischemic stroke, in a subset of 
patients.  
• We found no relationships between thrombin generation variables and circulating 
PMV concentrations.  
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8 FUTURE PERSPECTIVES 
8.1 HIGH ON-TREATMEANT PLATELET REACTIVITY TO CLOPIDOGREL 
It would be of high priority to confirm the association between HPR and CSVD in a larger 
study. Such a study should use MRI to assess the not only WMC but all the different CSVD 
manifestations and their respective associations with HPR. In particular, the association 
between HPR/platelet function and cerebral microbleeds in patients with IS/TIA is of interest, 
to determine whether patients with HPR and CSVD also have a risk of bleeding. Such a study 
could be designed as a case-control study with HPR patients as the cases.  
As HPR has a high prevalence in patients with IS/TIA, it should be investigated whether HPR 
status can be modified by interventions. Pilot crossover studies could be performed to 
investigate if metformin or the addition of dipyridamole or cilostazol to clopidogrel can 
reduce HPR prevalence. It would also be of interest to study the effect of life-style changes 
and more aggressive risk factor management in patients with HPR. Comparing the clinical 
effect of clopidogrel treatment versus aspirin combined with dipyridamole in IS/TIA patients 
with HPR would require a large, multicenter study. 
8.2 MICROVESICLES 
Study 3 illustrates both the potential and the complexity of subtyping MV to a greater level of 
detail than just cell of origin. In particular two aspects deserve further study. Firstly, the one 
population positively and independently associated with outcome, PS-TF+PMV, should be 
characterized further, and secondly the differences between PMV expressing respectively not 
expressing PS should be clarified. 
A more detailed characterization of PS-TF+PMV could include the investigation of other 
surface markers on these PMV, for instance PSGL-1 and neutrophil- and monocyte-specific 
markers. Also functional tests of this subpopulation are of interest. Possibly PS-TF+PMV 
could be isolated by lactadherin columns and/or magnetic beads with anti-TF antibodies, 
which could allow a more detailed characterization.  
The differences in dynamic behavior and association with outcome between PS+P-sel+PMV 
and PS-P-sel+PMV suggest that they may reflect different aspects of platelet activation. Also 
the negative correlation between PS+PMV and PS-P-sel+PMV merits further study. More 
detailed characterization of these PMV populations may provide clues to the mechanisms 
behind PS-PMV release, which are presently unknown. In particular it would be interesting to 
determine whether circulating levels of PS+P-sel+PMV correlate with the propensity to form 
PS+ procoagulant platelets in vitro and vice versa for PS-P-sel+PMV and PS- aggregating 
platelets.  
8.3 THROMBIN GENERATION VARIABLES 
It is possible that the contradictory results of study 4 could be clarified by investigating CAT 
response in PRP which would include platelet contribution to thrombin generation.  
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8.4 PLATELET MICROVESICLES, THROMBIN GENERATION AND VESSEL 
CHANGES 
Given the association between HPR and CSVD found in study 2, the associations between 
PMV respectively thrombin generation variables and existing vessel changes in the cohort of 
study 3 and 4 should be investigated. The data has been collected but not yet analyzed. If 
CSVD respectively large artery atherosclerosis have different ‘profiles’ of PMV populations 
and thrombin generation variables respectively, this may provide clues both to the underlying 
pathological mechanisms and possibly new treatment targets.  
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9 SVENSK SAMMANFATTNING 
Trombocyter (blodplättar) är centrala för kardiovaskulära sjukdomar som stroke. Vid stroke 
aktiveras trombocyter av en kärlskada och klumpar ihop sig (aggregerar) till en propp som 
blockerar blodförsörjningen till en del av hjärnan. Detta ger syrebrist, förlust av hjärnceller 
och funktionsbortfall. Stroke på grund av propp behandlas med läkemedel som hämmar 
trombocyternas förmåga att aggregera. Forskning visar att individer skiljer sig åt både vad 
gäller trombocyternas benägenhet att aggregera och hur väl trombocyter hämmas av 
behandling. Hos vissa patienter med hjärtkärlsjukdom bibehåller trombocyterna sin förmåga 
att aggregera trots behandling med trombocythämmande läkemedel. Detta gäller framför allt 
läkemedlet clopidogrel. De patienter som inte svarar på behandling kan betraktas som 
’clopidogrel-resistenta.’ Clopidogrel-resistens innebär en ökad risk för återinsjuknande. 
När trombocyter aktiveras kan de frisätta små blåsor från cellmembranet, så kallade 
mikrovesikler. Koncentrationen av trombocytmikrovesikler kan mätas i blod och speglar 
graden av trombocytaktivering. Aktiverade trombocyter och trombocytmikrovesikler kan i 
sin tur aktivera koagulationssystemet (blodlevringssystemet) som bildar enzymet trombin. 
Trombin bidrar till proppbildningen genom att bilda ett nätverk av fibrin; vidare stimulerar 
trombin trombocytaggregationen. Forskning tyder på att trombocyter och koagulation, utöver 
att bilda blodproppar, också bidrar till ateroskleros (åderförfettning), vilket är en 
underliggande orsak till både stroke och hjärtinfarkt. 
Det första målet med denna avhandling var undersöka förekomsten av clopidogrel-resistens 
hos patienter med stroke eller transient ischemisk attack (TIA), samt vilka faktorer som är 
kopplade till clopidogrel-resistens (studie 1 och 2). Vi fann clopidogrelresistens hos 22% av 
de 72 patienter vi undersökte, vilket är lika mycket eller något högre än vad man tidigare har 
funnit hos patienter med kranskärlssjukdom. Clopidogrel-resistenta patienter hade oftare 
diabetes och nedsatt glukostolerans än de med normalt svar på clopidogrel; omvänt var 
clopidogrel-resistens mycket ovanligt hos individer utan tecken på diabetes eller nedsatt 
glukostolerans. Clopidogrel-resistenta hade även högre insulinnivåer och högre blodtryck. 
Förekomsten av åderförfettning i halskärlen var inte högre hos clopidogrel-resistenta. 
Däremot var kärlsjukdom i hjärnans små kärl betydligt vanligare hos clopidogrel-resistenta 
patienter.  
Det andra målet var att undersöka trombocytmikrovesikler och trombinbildning efter stroke 
eller TIA och deras betydelse för återinsjuknande. Vi undersökte totalt 211 patienter och 
jämförde med 53 ålders- och könsmatchade friska kontroller. Patienterna hade betydligt 
högre koncentrationer i blod av trombocytmicrovesikler som bar på aktiveringsmarkörerna P-
selectin och tromboplastin (studie 3). Bara en typ av trombocytmikrovesikler var kopplad till 
återinsjuknande: höga nivåer trombocytmikrovesikler som bar på tromboplastin men inte 
fettmolekylen fosfatidylserin nästan dubblerade risken för återinsjuknande. Något oväntat 
verkade höga nivåer i blodet av flera andra typer av mikrovesikler ha en skyddande effekt.  
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Trombinbildningsförmågan i blodet var högre hos strokepatienter än hos friska individer. 
Trots detta visade studie 4 att hög trombinbildningsförmåga i den akuta fasen av stroke var 
förenat med en minskad risk för återfall. Däremot var mikrovesiklernas funktionella förmåga 
att bilda trombin kopplad till en ökad risk för återfall i stroke.  
Sammanfattningsvis är clopidogrel-resistens vanligt efter stroke/TIA och kan i vissa grupper 
finnas hos upp mot 40% av patienterna. Risken för clopidogrel-resistens ökar redan under 
förstadiet till diabetes. Förbättrad livsstil och mer intensiv behandling av riskfaktorer kan 
tänkas minska återfallsrisken för dessa patienter. Större studier behövs emellertid för att 
undersöka om andra trombocythämmande läkemedel än clopidogrel kan förbättra prognosen 
för strokepatienter med clopidogrelresistens. Studie 3 visar att en detaljerad kartläggning av 
trombocytmikropartiklar kan ge information om trombocytaktiveringen vid stroke/TIA. Vissa 
typer av trombocytmikrovesikler var kopplade till ökad respektive minskad risk för återfall. 
De bakomliggande mekanismerna är okända och bör kartläggas närmare, framför all vad 
gäller trombocytmikrovesikler som bär på tromboplastin men saknar fosfatidylserin, då dessa 
vesikler var kopplade till ökad risk för återfall. Hos patienter med hög risk för 
återinsjuknande är trombinbildningen störd i akutfasen av stroke/TIA, med tecken på nedsatt 
trombinbildningsförmåga.  
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
  

  69 
10 ACKNOWLEDGEMENTS 
I am grateful to so many people for their contributions to and support of my research. First 
and foremost the patients, without whom research would not be possible. 
My main supervisor Håkan Wallén – mercury-quick mind and razor blade thought. Thank 
you for taking me on as a PhD-student, for your dedication, thoroughness and for giving me 
the freedom to find my way as a scientist. Discussions with you always ignite new scientific 
ideas.   
Ann Charlotte Laska – co-supervisor, mentor and friend. Thank you for always being 
‘steady as a rock’ and helping me stay on track (despite my meandering ways). Your 
integrity, wisdom and immense clinical knowledge remain an inspiration to me as a scientist, 
doctor and human being. 
Bruna Gigante, my co-supervisor – thank you for sharing your impressive knowledge of 
epidemiology and for contributing your unique combination of stringence and Italian colour 
to all scientific discussions. 
Ola Winqvist, my co-supervisor and the one who got me started in medical research when I 
was still a student. Thank you for showing me the importance of thinking ‘outside of the box’ 
and your invaluable tips for writing this thesis.   
Magnus von Arbin – thank you for your encouragement, kindness and support. And for 
deciphering the fascinating CAA case that started my research at KIDS. 
Charlotte Thålin – thank you for being the best travel companion imaginable on the road to 
becoming a scientist as well as a dear friend! Your energy, support and never wavering 
enthusiasm brighten my life – and bring so much fun. And not least: without you this thesis 
would not be nearly as good-looking. 
Elisabeth Rooth, my esteemed colleague and now boss. Thank you for letting me ‘inherit’ 
your amazing data-base, a goldmine of information. Thank you also for always keeping a 
positive attitude, which makes both work and research easier. 
Fari Mobarrez – thank you for your never-ending patience in teaching me most of what I 
know about microvesicles – including tricks to analyze them when they are not in the mood! 
Working with you is always a delight and I look forward to future cooperation.  
The present and former research nurses of the stroke section: Eva Isaksson, Helena 
Kumpulainen, Anna Berg, Pernilla Becker and Hillevi Asplund. Without your help in 
keeping track of the StrokeDiabetes and PROPPSTOPP studies this thesis would not have 
been possible. 
The research staff and fellow researchers at KFC and KIDS: Katherina Aguilera, Lena 
Gabrielsson, Ann-Christin Salomonsson and Maud Daleskog – thank you for always 
 70 
being wellcoming and supportive, making a novice like me feel at home in the laboratory. 
Special thanks to Katherina who performed the CAT analyses of study 3. Sofie Paues 
Göransson – for exciting cooperation on neutrophil microvesicles. Gun Jörneskog – for all 
your help with my first paper. Meta Blombäck – for supporting my research and generally 
being a hemostasis legend and role model. Peter Henriksson, Sara Tehrani, Jan Svensson, 
Adriano Atterman and Lukasz Antoniewicz – for always interesting and fruitful scientific 
discussions.  
Evaldas Laurencikas, Karin Höeg Dembrower and Anders von Heijne from the X-ray 
department of Danderyd Hospital; thank you for excellent CT and MRI analyses.  
Lars Farde, my mentor, thank you for your support and interesting discussions on amyloids 
and how the brain talks to the blood. 
Johanna Möller, for the amazing thesis cover image, and my son Jakob Svensson, for help 
with the illustrations. 
Karolinska Institutet. Firstly for the privilege of attending the Research School for 
Clinicians, Molecular Biology. It truly developed me as a scientist and got me acquainted 
with so many amazing researchers and fellow PhD-studensts. Special thanks to Cecilia 
Berger, Emma Öberg and Maria Farm for great company and cooperation, and to our 
study director Erik Sundström for an excellent program. Many thanks also to the KIDS 
support staff, in particular Nina Ringart, Åsa Misic and statistician Fredrik Johansson.   
The specialists of the stroke section – for being such a great gang and for covering for me at 
the clinic this spring. Rebecca Undén Göransson, my former boss – thank you for 
supporting my resident research project (which started all this) and for your great sense of 
humor. Anna Grünfeldt – thank you for somehow always finding room in the schedule for 
research, and for imparting some serious culture to the group. Louise Ziegler – for your 
unique mix of breadth and depth and your ability of widening perspectives. Per Sandén for 
northern stability, patience and thoroughness. Per Wester, our guest professor, for promoting 
a scientific approach in the clinic. I am also grateful to present and former colleagues at the 
Hemostasis Center, in particular Eli Westerlund, Nina Olausson, Anna Ågren and Eva-
Lotta Hempel. Thank you for sharing your invaluable insights in coagulation and for you 
clinical excellence.  
The Clinic of Medicine at Danderyd Hospital,in particular: Anna von Döbeln for freeing 
time in the schedule, Lena Holmström for administrative support, and present and previous 
bosses during my PhD education who have supported research, Emilie Asplund, Andreas 
Kling, Mats Söderhäll and Karin Malmqvist.  
The people who taught me to think – often by unconventional methods! In particular: my 
father, Gunnar Lundström, in memoriam; Jim Kingdom, my first boss, in memoriam; 
  71 
Peter Behrmann, my colleague at Estec; Martin Cederwall and Mats Knapp – for 
encouraging intellectual curiosity. 
All the marvelous women in my life, without whose listening and support my thinking would 
not have born fruit. My mother Margita Lundström. Elsa Gustafsson, dear friend and sister 
in faith; without you my life would not be the same. Anna Swan, my closest friend from 
Chalmers. Katarina ‘Katten’ Ståhlgren, for reminding me of literature, art, love and life. 
Cecilia Blacker, I’m so glad we found each other when you were finding yourself. Pia 
Bergendahl, for your invaluable insights in the human psyche. Natasja Widén, for helping 
me contemplate work, research and life experiences.  
The fellow travelers in my second career who also became dear friends: Karin Åkerberg, 
Daniel Åkerberg, Katarina Groth, Sissela Liljeqvist, Anna Granzelius and Linda Löf.  
The friends, brightening and livening up non-research time during these years, and too many 
to mention. Elsa, Olle, Anna, Jim, Franco, Luisa, Katten, Björn, Pia, Janne, Per, Linna, 
Johanna, Gustaf, Kathy, Daniele, Gunilla, Magnus K, Helena, Greg, Natasja, Magnus 
B, Magnus L, Anders, Suze, Loj, Elisabeth and not least the culture cardigans Annika, 
Johan, Susanne and Tomas.  
My extended family! My siblings Petter, Elisabeth and Martin with their amazing families 
– you truly enrich my life. My in-laws: Ester, Lena, Janne, Sara and Johan with families; 
thank you for welcoming me into your lifes, for all the warmth and laughter. My colourful 
relatives; aunts, uncles and cousins with their families. You all give me roots and context.  
My immediate family – Bengt, Frida and Jakob. I love you so much and you bring so much 
joy to my life. Without you nothing would be possible.  
Finally, the research foundations supporting my research, in particular the Swedish Stroke 
Association and the Foundation for Coagulation Research at Karolinska Institutet. 
 
 

  73 
11 REFERENCES 
 
1. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. 
Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein 
E. Nat Med. 2003;9(1):61-7. 
2. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, et al. A critical 
role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 
2002;196(7):887-96. 
3. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. 
Hematology Am Soc Hematol Educ Program. 2011;2011:51-61. 
4. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et 
al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke 
or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, 
placebo-controlled trial. Lancet. 2004;364(9431):331-7. 
5. Investigators SPS, Benavente OR, Hart RG, McClure LA, Szychowski JM, 
Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar 
stroke. N Engl J Med. 2012;367(9):817-25. 
6. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and 
clinical outcome - fact and fiction. Thromb Haemost. 2011;106(2):191-202. 
7. Gross L, Aradi D, Sibbing D. Platelet Function Testing in Patients on 
Antiplatelet Medications. Semin Thromb Hemost. 2016;42(3):306-20. 
8. Evangelista V, Smyth SS. Interactions between platelets, leukocytes and the 
endothelium. In: Michelson AD, editor. Platelets: Elsevier Inc; 2013. p. 295-312. 
9. Morel O, Morel N, Freyssinet JM, Toti F. Platelet microparticles and vascular 
cells interactions: a checkpoint between the haemostatic and thrombotic responses. 
Platelets. 2008;19(1):9-23. 
10. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. 
Accumulation of tissue factor into developing thrombi in vivo is dependent upon 
microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 
2003;197(11):1585-98. 
11. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et 
al. An updated definition of stroke for the 21st century: a statement for healthcare 
professionals from the American Heart Association/American Stroke Association. Stroke. 
2013;44(7):2064-89. 
12. Riksstroke TSSR. Årsrapporter Umeå: Registercentrum Norr, Norrlands 
Universitetssjukhus; 2016 [cited 2018 04/29]. Available from: 
http://www.riksstroke.org/sve/forskning-statistik-och-
verksamhetsutveckling/rapporter/arsrapporter/. 
13. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. 
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J 
Med. 2008;359(12):1238-51. 
14. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et 
al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 
2016;375(1):35-43. 
15. O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. 
Global and regional effects of potentially modifiable risk factors associated with acute 
stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 
2016;388(10046):761-75. 
 74 
16. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a 
risk profile from the Framingham Study. Stroke. 1991;22(3):312-8. 
17. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, et al. 
Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic 
analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016;15(9):913-24. 
18. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, 
Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J 
Med. 2006;355(6):549-59. 
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart 
disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-
9. 
20. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of 
potentially modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. 
21. Ornello R, Degan D, Tiseo C, Di Carmine C, Perciballi L, Pistoia F, et al. 
Distribution and Temporal Trends From 1993 to 2015 of Ischemic Stroke Subtypes: A 
Systematic Review and Meta-Analysis. Stroke. 2018;49(4):814-9. 
22. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 
ESC Guidelines for the management of atrial fibrillation developed in collaboration with 
EACTS. Eur Heart J. 2016;37(38):2893-962. 
23. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial 
fibrillation: Virchow's triad revisited. Lancet. 2009;373(9658):155-66. 
24. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes 
for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish 
Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. 
25. Aspberg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison 
of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic 
stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 
2016;37(42):3203-10. 
26. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N 
Engl J Med. 2005;352(16):1685-95. 
27. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical 
characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701. 
28. Moran C, Phan TG, Srikanth VK. Cerebral small vessel disease: a review of 
clinical, radiological, and histopathological phenotypes. Int J Stroke. 2012;7(1):36-46. 
29. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et 
al. Neuroimaging standards for research into small vessel disease and its contribution to 
ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-38. 
30. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic 
whole-brain disease. Stroke Vasc Neurol. 2016;1(3):83-92. 
31. Debette S, Markus HS. The clinical importance of white matter 
hyperintensities on brain magnetic resonance imaging: systematic review and meta-
analysis. BMJ. 2010;341:c3666. 
32. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic 
review of differences in risk factor profiles between lacunar and nonlacunar infarcts. 
Stroke. 2005;36(4):891-901. 
33. Jackson CA, Hutchison A, Dennis MS, Wardlaw JM, Lindgren A, Norrving 
B, et al. Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct 
lacunar arteriopathy? Stroke. 2010;41(4):624-9. 
34. Wardlaw JM, Allerhand M, Doubal FN, Valdes Hernandez M, Morris Z, Gow 
AJ, et al. Vascular risk factors, large-artery atheroma, and brain white matter 
hyperintensities. Neurology. 2014;82(15):1331-8. 
  75 
35. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic 
component of ischemic stroke subtypes: a family history study. Stroke. 2003;34(6):1364-9. 
36. Traylor M, Bevan S, Baron JC, Hassan A, Lewis CM, Markus HS. Genetic 
Architecture of Lacunar Stroke. Stroke. 2015;46(9):2407-12. 
37. Tan R, Traylor M, Rutten-Jacobs L, Markus H. New insights into mechanisms 
of small vessel disease stroke from genetics. Clin Sci (Lond). 2017;131(7):515-31. 
38. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol. 
1968;12(1):1-15. 
39. Shi Y, Thrippleton MJ, Makin SD, Marshall I, Geerlings MI, de Craen AJ, et 
al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J 
Cereb Blood Flow Metab. 2016;36(10):1653-67. 
40. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular 
disease--systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337-52. 
41. van der Veen PH, Muller M, Vincken KL, Hendrikse J, Mali WP, van der 
Graaf Y, et al. Longitudinal relationship between cerebral small-vessel disease and cerebral 
blood flow: the second manifestations of arterial disease-magnetic resonance study. Stroke. 
2015;46(5):1233-8. 
42. van Leijsen EMC, de Leeuw FE, Tuladhar AM. Disease progression and 
regression in sporadic small vessel disease-insights from neuroimaging. Clin Sci (Lond). 
2017;131(12):1191-206. 
43. Mestre H, Kostrikov S, Mehta RI, Nedergaard M. Perivascular spaces, 
glymphatic dysfunction, and small vessel disease. Clin Sci (Lond). 2017;131(17):2257-74. 
44. Joutel A, Chabriat H. Pathogenesis of white matter changes in cerebral small 
vessel diseases: beyond vessel-intrinsic mechanisms. Clin Sci (Lond). 2017;131(8):635-51. 
45. Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med. 
1999;4(3):165-72. 
46. Oberheiden T, Blahak C, Nguyen XD, Fatar M, Elmas E, Morper N, et al. 
Activation of platelets and cellular coagulation in cerebral small-vessel disease. Blood 
Coagul Fibrinolysis. 2010;21(8):729-35. 
47. Ruggeri ZM, Jackson SP. Platelet thrombus formation in flowing blood. In: 
Michelson AD, editor. Platelets. 3 ed: Elsevier inc.; 2013. p. 399-424. 
48. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a 
technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 
2008;112(8):3011-25. 
49. Flaumenhaft R. Platelet secretion. In: Michelson AD, editor. Platelets. 3 ed: 
Elsevier Inc; 2013. p. 343-66. 
50. Brass LF, Newman DK, Wannemacher KM, Li Z, Stalker TJ. Signal 
transduction during platelet plug formation. In: Michelson AD, editor. Platelets. 3 ed: 
Elsevier Inc.; 2013. p. 367-98. 
51. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet 
activation in vivo is only partly counteracted by aspirin. Circulation. 1994;89(5):1951-7. 
52. Larsson PT, Wallen NH, Egberg N, Hjemdahl P. Alpha-adrenoceptor 
blockade by phentolamine inhibits adrenaline-induced platelet activation in vivo without 
affecting resting measurements. Clin Sci (Lond). 1992;82(4):369-76. 
53. Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet 
activation in whole blood. Blood Coagul Fibrinolysis. 1997;8(8):517-23. 
54. Westein E, Hoefer T, Calkin AC. Thrombosis in diabetes: a shear flow effect? 
Clin Sci (Lond). 2017;131(12):1245-60. 
55. Hoffman M, Monroe DM, 3rd. A cell-based model of hemostasis. Thromb 
Haemost. 2001;85(6):958-65. 
 76 
56. Bouchard BA, Silveira JR, Tracy PB. Interactions between platelets and the 
coagulation system. In: Michelson AD, editor. Platelets. 3 ed: Elsevier Inc.; 2013. p. 425-
52. 
57. Walsh PN. The role of platelets in blood coagulation. In: Marder VJ, Aird 
WC, Bennett JS, Schulman S, White GC, editors. Hemostasis and thrombosis. 6 ed: 
Lippincott Williams & Wilkins; 2013. p. 468-374. 
58. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid 
scrambling by TMEM16F. Nature. 2010;468(7325):834-8. 
59. Reviakine I. New horizons in platelet research: understanding and harnessing 
platelet functional diversity. Clin Hemorheol Microcirc. 2015;60(1):133-52. 
60. Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the 
granules ... or not? J Thromb Haemost. 2015;13(12):2141-51. 
61. Chargaff E, West R. The biological significance of the thromboplastic protein 
of blood. J Biol Chem. 1946;166(1):189-97. 
62. Wolf P. The nature and significance of platelet products in human plasma. Br 
J Haematol. 1967;13(3):269-88. 
63. Ridger VC, Boulanger CM, Angelillo-Scherrer A, Badimon L, Blanc-Brude 
O, Bochaton-Piallat ML, et al. Microvesicles in vascular homeostasis and diseases. Position 
Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and 
Vascular Biology. Thromb Haemost. 2017;117(7):1296-316. 
64. Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in 
coronary artery disease. Nat Rev Cardiol. 2017;14(5):259-72. 
65. Siljander PR. Platelet-derived microparticles - an updated perspective. 
Thromb Res. 2011;127 Suppl 2:S30-3. 
66. Thulin A, Christersson C, Alfredsson J, Siegbahn A. Circulating cell-derived 
microparticles as biomarkers in cardiovascular disease. Biomark Med. 2016;10(9):1009-22. 
67. Mobarrez F, He S, Broijersen A, Wiklund B, Antovic A, Antovic J, et al. 
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and 
GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive 
disease. Thromb Haemost. 2011;106(2):344-52. 
68. Connor DE, Exner T, Ma DD, Joseph JE. The majority of circulating platelet-
derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant 
activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost. 
2010;103(5):1044-52. 
69. Arraud N, Linares R, Tan S, Gounou C, Pasquet JM, Mornet S, et al. 
Extracellular vesicles from blood plasma: determination of their morphology, size, 
phenotype and concentration. J Thromb Haemost. 2014;12(5):614-27. 
70. Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-
derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 
1991;266(26):17261-8. 
71. Hoffman M, Monroe DM, Roberts HR. Coagulation factor IXa binding to 
activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb 
Haemost. 1992;68(1):74-8. 
72. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the 
platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. 
Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem. 
1989;264(29):17049-57. 
73. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, 
Krymskaya OV, et al. Platelet microparticle membranes have 50- to 100-fold higher 
specific procoagulant activity than activated platelets. Thromb Haemost. 2007;97(3):425-
34. 
  77 
74. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. 
Comparison of anticoagulant and procoagulant activities of stimulated platelets and 
platelet-derived microparticles. Blood. 1991;77(12):2641-8. 
75. Rank A, Nieuwland R, Crispin A, Grutzner S, Iberer M, Toth B, et al. 
Clearance of platelet microparticles in vivo. Platelets. 2011;22(2):111-6. 
76. Zaldivia MTK, McFadyen JD, Lim B, Wang X, Peter K. Platelet-Derived 
Microvesicles in Cardiovascular Diseases. Front Cardiovasc Med. 2017;4:74. 
77. Dasgupta SK, Abdel-Monem H, Niravath P, Le A, Bellera RV, Langlois K, et 
al. Lactadherin and clearance of platelet-derived microvesicles. Blood. 2009;113(6):1332-9. 
78. Dasgupta SK, Le A, Chavakis T, Rumbaut RE, Thiagarajan P. Developmental 
endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the 
endothelium. Circulation. 2012;125(13):1664-72. 
79. Flaumenhaft R, Dilks JR, Richardson J, Alden E, Patel-Hett SR, Battinelli E, 
et al. Megakaryocyte-derived microparticles: direct visualization and distinction from 
platelet-derived microparticles. Blood. 2009;113(5):1112-21. 
80. Skeppholm M, Mobarrez F, Malmqvist K, Wallen H. Platelet-derived 
microparticles during and after acute coronary syndrome. Thromb Haemost. 
2012;107(6):1122-9. 
81. Kuriyama N, Nagakane Y, Hosomi A, Ohara T, Kasai T, Harada S, et al. 
Evaluation of factors associated with elevated levels of platelet-derived microparticles in 
the acute phase of cerebral infarction. Clin Appl Thromb Hemost. 2010;16(1):26-32. 
82. Chen Y, Xiao Y, Lin Z, Xiao X, He C, Bihl JC, et al. The Role of Circulating 
Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients. J Stroke 
Cerebrovasc Dis. 2015;24(10):2313-20. 
83. van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, et al. P-
selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral 
arterial disease and myocardial infarction. Clin Chem. 2006;52(4):657-64. 
84. Boilard E, Duchez AC, Brisson A. The diversity of platelet microparticles. 
Curr Opin Hematol. 2015;22(5):437-44. 
85. Edelstein LC. The role of platelet microvesicles in intercellular 
communication. Platelets. 2017;28(3):222-7. 
86. Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, et 
al. Determination of plasma tissue factor antigen and its clinical significance. Br J 
Haematol. 1994;87(2):343-7. 
87. Fareed J, Callas DD, Hoppensteadt D, Bermes EW, Jr. Tissue factor antigen 
levels in various biological fluids. Blood Coagul Fibrinolysis. 1995;6 Suppl 1:S32-6. 
88. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. 
Tissue factor activity in whole blood. Blood. 2005;105(7):2764-70. 
89. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. 
Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 
1999;96(5):2311-5. 
90. Zwicker JI, Trenor CC, 3rd, Furie BC, Furie B. Tissue factor-bearing 
microparticles and thrombus formation. Arterioscler Thromb Vasc Biol. 2011;31(4):728-
33. 
91. Owens AP, 3rd, Mackman N. Microparticles in hemostasis and thrombosis. 
Circ Res. 2011;108(10):1284-97. 
92. Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front 
Biosci (Elite Ed). 2012;4:289-99. 
93. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-
coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci 
U S A. 2000;97(25):13835-40. 
 78 
94. Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, 
Camphausen RT, Widom A, et al. Interaction of P-selectin and PSGL-1 generates 
microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 
2003;9(8):1020-5. 
95. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, et al. 
Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel 
wall. Blood. 2005;105(1):192-8. 
96. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing 
microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. 
Blood. 2005;106(5):1604-11. 
97. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, et al. 
Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. 
FASEB J. 2003;17(3):476-8. 
98. Basavaraj MG, Olsen JO, Osterud B, Hansen JB. Differential ability of tissue 
factor antibody clones on detection of tissue factor in blood cells and microparticles. 
Thromb Res. 2012;130(3):538-46. 
99. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator 
of atherosclerosis. N Engl J Med. 2011;364(18):1746-60. 
100. Egorina EM, Sovershaev MA, Osterud B. Regulation of tissue factor 
procoagulant activity by post-translational modifications. Thromb Res. 2008;122(6):831-7. 
101. Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis 
and Trigger of Thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709-25. 
102. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 
2008;359(9):938-49. 
103. Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is 
required for platelet thrombus propagation but not fibrin generation in a mouse model of 
thrombosis. Proc Natl Acad Sci U S A. 2007;104(1):288-92. 
104. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyte-versus 
microparticle-mediated tissue factor transfer during arteriolar thrombus development. J 
Leukoc Biol. 2005;78(6):1318-26. 
105. Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived 
protein disulfide isomerase is required for thrombus formation in vivo. Blood. 
2010;116(22):4665-74. 
106. Bowley SR, Fang C, Merrill-Skoloff G, Furie BC, Furie B. Protein disulfide 
isomerase secretion following vascular injury initiates a regulatory pathway for thrombus 
formation. Nat Commun. 2017;8:14151. 
107. Behnke O, Forer A. Blood platelet heterogeneity: evidence for two classes of 
platelets in man and rat. Br J Haematol. 1993;84(4):686-93. 
108. Behnke O. Blood platelet heterogeneity: a functional hierarchy in the platelet 
population. Br J Haematol. 1995;91(4):991-9. 
109. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. 
Collagen but not fibrinogen surfaces induce bleb formation, exposure of 
phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation 
by protein tyrosine kinase-dependent Ca2+ responses. Blood. 1997;90(7):2615-25. 
110. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, et al. 
Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the 
cell surface. Nature. 2002;415(6868):175-9. 
111. Dale GL. Coated-platelets: an emerging component of the procoagulant 
response. J Thromb Haemost. 2005;3(10):2185-92. 
112. Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: 
variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc 
Biol. 2005;25(4):861-6. 
  79 
113. Munnix IC, Kuijpers MJ, Auger J, Thomassen CM, Panizzi P, van Zandvoort 
MA, et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus 
formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. 
2007;27(11):2484-90. 
114. Agbani EO, van den Bosch MT, Brown E, Williams CM, Mattheij NJ, 
Cosemans JM, et al. Coordinated Membrane Ballooning and Procoagulant Spreading in 
Human Platelets. Circulation. 2015;132(15):1414-24. 
115. Agbani EO, Williams CM, Hers I, Poole AW. Membrane Ballooning in 
Aggregated Platelets is Synchronised and Mediates a Surge in Microvesiculation. Sci Rep. 
2017;7(1):2770. 
116. Yakimenko AO, Verholomova FY, Kotova YN, Ataullakhanov FI, Panteleev 
MA. Identification of different proaggregatory abilities of activated platelet subpopulations. 
Biophys J. 2012;102(10):2261-9. 
117. Agbani EO, Poole AW. Procoagulant platelets: generation, function, and 
therapeutic targeting in thrombosis. Blood. 2017;130(20):2171-9. 
118. Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-
independent platelet adhesion and aggregation under elevated shear stress. Blood. 
2006;108(6):1903-10. 
119. Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, Jackson SP. 
Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus 
formation. Blood. 2007;109(2):566-76. 
120. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, 
Zimmerman GA, et al. Activated platelets mediate inflammatory signaling by regulated 
interleukin 1beta synthesis. J Cell Biol. 2001;154(3):485-90. 
121. Vajen T, Mause SF, Koenen RR. Microvesicles from platelets: novel drivers 
of vascular inflammation. Thromb Haemost. 2015;114(2):228-36. 
122. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, 
et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5. 
123. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. 
Nat Rev Immunol. 2018;18(2):134-47. 
124. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. 
Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. 
Nat Med. 2007;13(4):463-9. 
125. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate 
immunity. Nat Rev Immunol. 2013;13(1):34-45. 
126. Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki 
S, et al. Expression of functional tissue factor by neutrophil extracellular traps in culprit 
artery of acute myocardial infarction. Eur Heart J. 2015;36(22):1405-14. 
127. Valles J, Lago A, Santos MT, Latorre AM, Tembl JI, Salom JB, et al. 
Neutrophil extracellular traps are increased in patients with acute ischemic stroke: 
prognostic significance. Thromb Haemost. 2017;117(10):1919-29. 
128. Ducroux C, Di Meglio L, Loyau S, Delbosc S, Boisseau W, Deschildre C, et 
al. Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in 
Acute Ischemic Stroke. Stroke. 2018;49(3):754-7. 
129. Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules 
contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular 
eukaryotes. J Biol Chem. 2004;279(43):44250-7. 
130. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, et al. 
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 
2009;139(6):1143-56. 
 80 
131. Faxalv L, Boknas N, Strom JO, Tengvall P, Theodorsson E, Ramstrom S, et 
al. Putting polyphosphates to the test: evidence against platelet-induced activation of factor 
XII. Blood. 2013;122(23):3818-24. 
132. Morrissey JH, Smith SA. Polyphosphate as modulator of hemostasis, 
thrombosis, and inflammation. J Thromb Haemost. 2015;13 Suppl 1:S92-7. 
133. Verhoef JJ, Barendrecht AD, Nickel KF, Dijkxhoorn K, Kenne E, Labberton 
L, et al. Polyphosphate nanoparticles on the platelet surface trigger contact system 
activation. Blood. 2017;129(12):1707-17. 
134. Labberton L, Kenne E, Long AT, Nickel KF, Di Gennaro A, Rigg RA, et al. 
Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. Nat 
Commun. 2016;7:12616. 
135. Davi G, Santilli F, Vazzana N. The role of platelets in disease: Diabetes 
Mellitus. In: Michelson AD, editor. Platelets. 3 ed: Elsevier Inc.; 2013. p. 711-32. 
136. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, et al. 
Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 
1990;322(25):1769-74. 
137. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. 
Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in 
vivo. Diabetes. 1988;37(6):780-6. 
138. Hiramatsu K, Nozaki H, Arimori S. Reduction of platelet aggregation induced 
by euglycaemic insulin clamp. Diabetologia. 1987;30(5):310-3. 
139. Westerbacka J, Yki-Jarvinen H, Turpeinen A, Rissanen A, Vehkavaara S, 
Syrjala M, et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin 
abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol. 2002;22(1):167-
72. 
140. Yngen M, Li N, Hjemdahl P, Wallen NH. Insulin enhances platelet activation 
in vitro. Thromb Res. 2001;104(2):85-91. 
141. Spectre G, Ostenson CG, Li N, Hjemdahl P. Postprandial platelet activation is 
related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes. 
Diabetes. 2012;61(9):2380-4. 
142. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-
Quevedo P, et al. Insulin therapy is associated with platelet dysfunction in patients with 
type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 
2006;48(2):298-304. 
143. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by 
hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17(8):577-85. 
144. Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of 
hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and 
platelet CD40 ligand. Diabetes. 2006;55(1):202-8. 
145. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J 
Thromb Haemost. 2012;10(2):167-76. 
146. Pastori D, Pignatelli P, Carnevale R, Violi F. Nox-2 up-regulation and platelet 
activation: Novel insights. Prostaglandins Other Lipid Mediat. 2015;120:50-5. 
147. Magwenzi S, Woodward C, Wraith KS, Aburima A, Raslan Z, Jones H, et al. 
Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the 
cGMP/protein kinase G signaling cascade. Blood. 2015;125(17):2693-703. 
148. Pedreno J, Hurt-Camejo E, Wiklund O, Badimon L, Masana L. Low-density 
lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. Evidence that 
the proaggregatory effect induced by LDL is modulated by down-regulation of binding 
sites and desensitization of its mediated signaling. Atherosclerosis. 2001;155(1):99-112. 
  81 
149. Yang M, Cooley BC, Li W, Chen Y, Vasquez-Vivar J, Scoggins NO, et al. 
Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic 
conditions. Blood. 2017;129(21):2917-27. 
150. Ahmadsei M, Lievens D, Weber C, von Hundelshausen P, Gerdes N. 
Immune-mediated and lipid-mediated platelet function in atherosclerosis. Curr Opin 
Lipidol. 2015;26(5):438-48. 
151. Mineo C, Shaul PW. Regulation of signal transduction by HDL. J Lipid Res. 
2013;54(9):2315-24. 
152. Viera-de-Abreu A, Rondina MT, Weyrich AS, Zimmermann GA. The role of 
platelets in disease: Inflammation. In: Michelson AD, editor. Platelets. 3 ed: Elsevier Inc.; 
2013. p. 733-66. 
153. Yeaman MR, Bayer AS. The role of platelets in disease: antimicrobial host 
defense. In: Michelson AD, editor. Platelets. 3 ed: Elsevier Inc.; 2013. p. 767-802. 
154. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol. 
2008;28(3):s11-6. 
155. Schrottmaier WC, Kral JB, Badrnya S, Assinger A. Aspirin and P2Y12 
Inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost. 
2015;114(3):478-89. 
156. Ho-Tin-Noe B, Demers M, Wagner DD. How platelets safeguard vascular 
integrity. J Thromb Haemost. 2011;9 Suppl 1:56-65. 
157. El Haouari M, Rosado JA. Platelet function in hypertension. Blood Cells Mol 
Dis. 2009;42(1):38-43. 
158. Harrison P, Lordkipanidze M. Clinical tests of platelet function. In: Michelson 
AD, editor. Platelets. 3 ed: Elsevier Inc.; 2013. p. 519-46. 
159. Berny-Lang MA, Freilinger ALI, Barnard MR, Michelson AD. Tests of 
platelet function: flow cytometry. In: Michelson AD, editor. Platelets. 3 ed: Elsevier Inc.; 
2013. p. 581-602. 
160. Dasgupta SK, Guchhait P, Thiagarajan P. Lactadherin binding and 
phosphatidylserine expression on cell surface-comparison with annexin A5. Transl Res. 
2006;148(1):19-25. 
161. Coumans FAW, Brisson AR, Buzas EI, Dignat-George F, Drees EEE, El-
Andaloussi S, et al. Methodological Guidelines to Study Extracellular Vesicles. Circ Res. 
2017;120(10):1632-48. 
162. Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, et 
al. A microchip flow-chamber system for quantitative assessment of the platelet thrombus 
formation process. Microvasc Res. 2012;83(2):154-61. 
163. Gurbel PA, Tantry US. Monitoring of antiplatelet therapy. In: Michelson AD, 
editor. Platelets. 3 ed: Elsevier Inc.; 2013. p. 603-34. 
164. Cattaneo  M. ADP receptor antagonists. In: Michelson AD, editor. Platelets. 3 
ed: Elsevier Inc.; 2013. p. 1117-38. 
165. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: 
evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503-9. 
166. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. 
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 
2009;361(11):1045-57. 
167. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb 
S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J 
Med. 2007;357(20):2001-15. 
168. Eisert WG. Dipyridamole. In: Michelson AD, editor. Platelets. 3 ed: Elsevier 
Inc.; 2013. p. 1155-71. 
 82 
169. Ikeda Y, Sudo T, Kimura Y. Cilostazol. In: Michelson AD, editor. Platelets. 3 
ed: Elevier Inc.; 2013. p. 1171-84. 
170. Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for 
secondary prevention of vascular events after stroke of arterial origin. Cochrane Database 
Syst Rev. 2011(1):CD008076. 
171. Bavry AA. GPIIbIIIa antagonists. In: Michelson AD, editor. Platelets. 3 ed: 
Elsevier Inc.; 2013. p. 1139-54. 
172. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: why 
don't they work? Am J Cardiovasc Drugs. 2001;1(6):421-8. 
173. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, et al. 
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a 
randomised, double-blind, parallel-group trial. Lancet. 2011;377(9782):2013-22. 
174. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et 
al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 
2012;366(1):20-33. 
175. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, 
McClelland TJ, et al. Aspirin response and failure in cerebral infarction. Stroke. 
1993;24(3):345-50. 
176. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et 
al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 
1994;25(12):2331-6. 
177. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of 
platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002;252(3):233-8. 
178. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary 
stenting: response variability, drug resistance, and the effect of pretreatment platelet 
reactivity. Circulation. 2003;107(23):2908-13. 
179. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials 
of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk 
patients. BMJ. 2002;324(7329):71-86. 
180. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. 
Comparison of platelet function tests in predicting clinical outcome in patients undergoing 
coronary stent implantation. JAMA. 2010;303(8):754-62. 
181. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, 
Diodati JG. A comparison of six major platelet function tests to determine the prevalence of 
aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 
2007;28(14):1702-8. 
182. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. 
Consensus and future directions on the definition of high on-treatment platelet reactivity to 
adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919-33. 
183. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" 
and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 
2008;336(7637):195-8. 
184. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, 
et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous 
coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160(3):543-
51. 
185. Patrono C. Aspirin. In: Michelson AD, editor. Platelets. 3 ed: Elsevier Inc.; 
2013. p. 1099-116. 
186. Jeong YH, Park Y, Bliden KP, Tantry US, Gurbel PA. High platelet reactivity 
to multiple agonists during aspirin and clopidogrel treatment is indicative of a global 
hyperreactive platelet phenotype. Heart. 2012;98(4):343; author reply -4. 
  83 
187. Cattaneo M. Mechanisms of variability in antiplatelet agents response. 
Thromb Res. 2012;130 Suppl 1:S27-8. 
188. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-
induced platelet aggregation can be mediated by vWF released from platelets, as well as by 
exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is 
resistant to aspirin. Blood. 1988;71(5):1366-74. 
189. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. 
Compliance as a critical consideration in patients who appear to be resistant to aspirin after 
healing of myocardial infarction. Am J Cardiol. 2005;95(8):973-5. 
190. Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US. The 
relation between CYP2C19 genotype and phenotype in stented patients on maintenance 
dual antiplatelet therapy. Am Heart J. 2011;161(3):598-604. 
191. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, 
et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and 
clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-57. 
192. Bhatt DL, Pare G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. 
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes 
in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50. 
193. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. 
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 
2010;363(20):1909-17. 
194. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, et al. Bedside 
monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 
2012;367(22):2100-9. 
195. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne 
C, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented 
for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, 
randomised controlled superiority trial. Lancet. 2016;388(10055):2015-22. 
196. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. 
Consensus and update on the definition of on-treatment platelet reactivity to adenosine 
diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261-
73. 
197. Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A. Platelet 
aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated 
patients: initial evidence of a therapeutic window. J Am Coll Cardiol. 2010;56(4):317-8. 
198. Del Zoppo GJ. The role of platelets in disease: central nervous system 
ischemia. In: Michelson AD, editor. Platelets. 3 ed: Elsevier Inc.; 2013. p. 669-98. 
199. Grau AJ, Ruf A, Vogt A, Lichy C, Buggle F, Patscheke H, et al. Increased 
fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. 
Thromb Haemost. 1998;80(2):298-301. 
200. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased 
activation in patients with acute cerebral ischemia. Thromb Haemost. 1999;81(3):373-7. 
201. Meiklejohn DJ, Vickers MA, Morrison ER, Dijkhuisen R, Moore I, Urbaniak 
SJ, et al. In vivo platelet activation in atherothrombotic stroke is not determined by 
polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol. 2001;112(3):621-
31. 
202. Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, 
Stumpf C, et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute 
cerebral ischemia. Stroke. 2003;34(6):1412-8. 
203. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. 
Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa 
 84 
blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 
2007;115(17):2323-30. 
204. Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation 
mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost. 2011;9 Suppl 
1:92-104. 
205. Adams HP, Jr., Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al. 
Emergency administration of abciximab for treatment of patients with acute ischemic 
stroke: results of an international phase III trial: Abciximab in Emergency Treatment of 
Stroke Trial (AbESTT-II). Stroke. 2008;39(1):87-99. 
206. Lim ST, Coughlan CA, Murphy SJ, Fernandez-Cadenas I, Montaner J, Thijs 
V, et al. Platelet function testing in transient ischaemic attack and ischaemic stroke: A 
comprehensive systematic review of the literature. Platelets. 2015;26(5):402-12. 
207. Fiolaki A, Katsanos AH, Kyritsis AP, Papadaki S, Kosmidou M, Moschonas 
IC, et al. High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: 
A systematic review and meta-analysis. J Neurol Sci. 2017;376:112-6. 
208. Taglieri N, Bacchi Reggiani ML, Palmerini T, Ghetti G, Saia F, Gallo P, et al. 
Risk of stroke in patients with high on-clopidogrel platelet reactivity to adenosine 
diphosphate after percutaneous coronary intervention. Am J Cardiol. 2014;113(11):1807-
14. 
209. Depta JP, Fowler J, Novak E, Katzan I, Bakdash S, Kottke-Marchant K, et al. 
Clinical outcomes using a platelet function-guided approach for secondary prevention in 
patients with ischemic stroke or transient ischemic attack. Stroke. 2012;43(9):2376-81. 
210. Maruyama H, Fukuoka T, Deguchi I, Ohe Y, Nagoya H, Kato Y, et al. Dual 
antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in 
patients with ischemic stroke. Intern Med. 2013;52(10):1043-7. 
211. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in 
patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 
1996;348(9038):1329-39. 
212. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European 
Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary 
prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13. 
213. Group ES, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. 
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin 
(ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665-73. 
214. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with 
aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11-9. 
215. Johnston SC, Amarenco P. Ticagrelor versus Aspirin in Acute Stroke or 
Transient Ischemic Attack. N Engl J Med. 2016;375(14):1395. 
216. Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen 
RA, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus 
clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia 
(TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 
2018;391(10123):850-9. 
217. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of 
aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and 
ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016;388(10042):365-
75. 
218. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. 
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack 
of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, 
controlled trial. Lancet Neurol. 2017;16(4):301-10. 
  85 
219. Doliwa Sobocinski P, Anggardh Rooth E, Frykman Kull V, von Arbin M, 
Wallen H, Rosenqvist M. Improved screening for silent atrial fibrillation after ischaemic 
stroke. Europace. 2012;14(8):1112-6. 
220. Rooth E, Sobocinski-Doliwa P, Antovic J, Frykman Kull V, Von Arbin M, 
Rosenqvist M, et al. Thrombin generation in acute cardioembolic and non-cardioembolic 
ischemic stroke. Scand J Clin Lab Invest. 2013;73(7):576-84. 
221. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, et al. 
Assessment of ADP-induced platelet aggregation with light transmission aggregometry and 
multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb 
Haemost. 2008;99(1):121-6. 
222. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet 
reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-
eluting stent thrombosis. J Am Coll Cardiol. 2009;53(10):849-56. 
223. Mobarrez F, Antovic J, Egberg N, Hansson M, Jorneskog G, Hultenby K, et 
al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. 
Thromb Res. 2010;125(3):e110-6. 
224. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et 
al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and 
hypocoagulability. Pathophysiol Haemost Thromb. 2002;32(5-6):249-53. 
225. World Health Organisation. Definition and diagnosis of diabetes and 
intermediate hyperglycemia Geneva Switzerland2006 [cited 2018 04/28]. Available from: 
http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabet
es_new.pdf. 
226. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner 
RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. 
227. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et 
al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter 
clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 
1993;24(1):35-41. 
228. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal 
abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 
1987;149(2):351-6. 
229. Wattjes MP, Henneman WJ, van der Flier WM, de Vries O, Traber F, Geurts 
JJ, et al. Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 
64-detector row CT. Radiology. 2009;253(1):174-83. 
230. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, 
Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and 
coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 
2005;54(8):2430-5. 
231. Meves SH, Schroder KD, Endres HG, Krogias C, Kruger JC, Neubauer H. 
Clopidogrel high-on-treatment platelet reactivity in acute ischemic stroke patients. Thromb 
Res. 2014;133(3):396-401. 
232. Ueno M, Fujita K, Yamamoto H, Ikeda T, Suga T, Yamaji K, et al. Impact of 
impaired glucose tolerance on clopidogrel response in patients with coronary artery disease. 
J Thromb Thrombolysis. 2015;40(2):174-81. 
233. Raturi A, Miersch S, Hudson JW, Mutus B. Platelet microparticle-associated 
protein disulfide isomerase promotes platelet aggregation and inactivates insulin. Biochim 
Biophys Acta. 2008;1778(12):2790-6. 
 86 
234. Essex DW, Chen K, Swiatkowska M. Localization of protein disulfide 
isomerase to the external surface of the platelet plasma membrane. Blood. 
1995;86(6):2168-73. 
235. Sousa HR, Gaspar RS, Sena EM, da Silva SA, Fontelles JL, AraUjo TL, et al. 
Novel antiplatelet role for a protein disulfide isomerase-targeted peptide: evidence of 
covalent binding to the C-terminal CGHC redox motif. J Thromb Haemost. 
2017;15(4):774-84. 
236. Kukula K, Klopotowski M, Was J, Wrobel A, Jamiolkowski J, Debski A, et 
al. Factors related to on-treatment platelet aggregation assessed by multiple electrode 
aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin. 
Postepy Kardiol Interwencyjnej. 2017;13(3):210-7. 
237. Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, et al. 
Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS 
patients undergoing stent implantation. Vascul Pharmacol. 2016;77:48-53. 
238. Holme PA, Orvim U, Hamers MJ, Solum NO, Brosstad FR, Barstad RM, et 
al. Shear-induced platelet activation and platelet microparticle formation at blood flow 
conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol. 
1997;17(4):646-53. 
239. Kafian S, Mobarrez F, Wallen H, Samad B. Association between platelet 
reactivity and circulating platelet-derived microvesicles in patients with acute coronary 
syndrome. Platelets. 2015;26(5):467-73. 
240. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, 
et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on 
Myocardial Revascularization of the European Society of Cardiology (ESC) and the 
European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special 
contribution of the European Association of Percutaneous Cardiovascular Interventions 
(EAPCI). Eur Heart J. 2014;35(37):2541-619. 
241. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 
2015 ESC Guidelines for the management of acute coronary syndromes in patients 
presenting without persistent ST-segment elevation: Task Force for the Management of 
Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment 
Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. 
242. Leon C, Alex M, Klocke A, Morgenstern E, Moosbauer C, Eckly A, et al. 
Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood. 
2004;103(2):594-600. 
243. Nekludov M, Mobarrez F, Gryth D, Bellander BM, Wallen H. Formation of 
microparticles in the injured brain of patients with severe isolated traumatic brain injury. J 
Neurotrauma. 2014;31(23):1927-33. 
244. Loeffen R, Winckers K, Ford I, Jukema JW, Robertson M, Stott DJ, et al. 
Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in 
Elderly Patients: Results From the PROSPER Study. J Gerontol A Biol Sci Med Sci. 
2015;70(8):982-8. 
245. Smid M, Dielis AW, Winkens M, Spronk HM, van Oerle R, Hamulyak K, et 
al. Thrombin generation in patients with a first acute myocardial infarction. J Thromb 
Haemost. 2011;9(3):450-6. 
246. Winckers K, ten Cate H, Hackeng TM. The role of tissue factor pathway 
inhibitor in atherosclerosis and arterial thrombosis. Blood Rev. 2013;27(3):119-32. 
247. Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George 
F, et al. Standardization of pre-analytical variables in plasma microparticle determination: 
results of the International Society on Thrombosis and Haemostasis SSC Collaborative 
workshop. J Thromb Haemost. 2013. 
  87 
248. Hellum M, Franco-Lie I, Ovstebo R, Hauge T, Henriksson CE. The effect of 
corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on 
microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy 
controls. PLoS One. 2017;12(9):e0184579. 
 
